https://trial.medpath.com/news/macrophage-cell-therapy-shows-70-transplant-free-survival-rate-in-advanced-liver-disease-trial 2026-05-26T06:17:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/macrophage-cell-therapy-shows-70-transplant-free-survival-rate-in-advanced-liver-disease-trial 2026-05-26T06:17:45+00:00 hourly 0.9 https://trial.medpath.com/news/nfl-biosciences-achieves-30-higher-efficacy-than-champix-in-biomarker-positive-smoking-cessation-population 2026-05-26T06:17:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nfl-biosciences-achieves-30-higher-efficacy-than-champix-in-biomarker-positive-smoking-cessation-population 2026-05-26T06:17:16+00:00 hourly 0.9 https://trial.medpath.com/news/ugandan-biotech-company-files-us-patent-for-multi-strain-ebola-mrna-vaccine-platform 2026-05-26T06:16:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ugandan-biotech-company-files-us-patent-for-multi-strain-ebola-mrna-vaccine-platform 2026-05-26T06:16:26+00:00 hourly 0.9 https://trial.medpath.com/news/obinutuzumab-b-mil62-shows-93-1-relapse-risk-reduction-in-phase-3-trial-for-aqp4-igg-nmosd 2026-05-26T06:14:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/obinutuzumab-b-mil62-shows-93-1-relapse-risk-reduction-in-phase-3-trial-for-aqp4-igg-nmosd 2026-05-26T06:14:05+00:00 hourly 0.9 https://trial.medpath.com/news/biocardia-s-cardiamp-cell-therapy-shows-sustained-exercise-improvements-in-refractory-angina-patients 2026-05-26T06:12:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocardia-s-cardiamp-cell-therapy-shows-sustained-exercise-improvements-in-refractory-angina-patients 2026-05-26T06:12:59+00:00 hourly 0.9 https://trial.medpath.com/news/menarini-group-to-present-comprehensive-oncology-data-at-asco-2026-featuring-elacestrant-combination-studies 2026-05-26T06:11:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/menarini-group-to-present-comprehensive-oncology-data-at-asco-2026-featuring-elacestrant-combination-studies 2026-05-26T06:11:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-datroway-as-first-trop2-directed-adc-for-first-line-triple-negative-breast-cancer-treatment 2026-05-26T06:11:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-datroway-as-first-trop2-directed-adc-for-first-line-triple-negative-breast-cancer-treatment 2026-05-26T06:11:45+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-drug-regulator-recommends-discontinuation-of-crizanlizumab-following-failed-efficacy-trial 2026-05-26T06:10:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-s-drug-regulator-recommends-discontinuation-of-crizanlizumab-following-failed-efficacy-trial 2026-05-26T06:10:23+00:00 hourly 0.9 https://trial.medpath.com/news/treefrog-therapeutics-tfg-001-shows-rapid-dopamine-release-and-enhanced-reinnervation-in-parkinson-s-disease-models 2026-05-26T06:09:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/treefrog-therapeutics-tfg-001-shows-rapid-dopamine-release-and-enhanced-reinnervation-in-parkinson-s-disease-models 2026-05-26T06:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/strainx-bioworks-raises-13-million-to-scale-precision-fermentation-platform-for-alternative-protein-production 2026-05-26T06:09:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/strainx-bioworks-raises-13-million-to-scale-precision-fermentation-platform-for-alternative-protein-production 2026-05-26T06:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/revvity-expands-precision-oncology-portfolio-with-new-cancer-test-launches-amid-steady-diagnostics-demand 2026-05-26T06:07:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revvity-expands-precision-oncology-portfolio-with-new-cancer-test-launches-amid-steady-diagnostics-demand 2026-05-26T06:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/calibrating-microglia-states-in-alzheimer-s-disease-from-anti-amyloid-antibodies-to-multi-target-microenvironment-protection 2026-05-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/calibrating-microglia-states-in-alzheimer-s-disease-from-anti-amyloid-antibodies-to-multi-target-microenvironment-protection 2026-05-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sakar-healthcare-expands-oncology-reach-with-zydus-lifesciences-partnership-for-gcc-markets 2026-05-24T14:46:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sakar-healthcare-expands-oncology-reach-with-zydus-lifesciences-partnership-for-gcc-markets 2026-05-24T14:46:58+00:00 hourly 0.9 https://trial.medpath.com/news/semnur-pharmaceuticals-secures-100-million-strategic-investment-from-iholding-group-to-advance-non-opioid-pain-therapy-semdexa 2026-05-24T14:32:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/semnur-pharmaceuticals-secures-100-million-strategic-investment-from-iholding-group-to-advance-non-opioid-pain-therapy-semdexa 2026-05-24T14:32:13+00:00 hourly 0.9 https://trial.medpath.com/news/ultra-low-dose-immunotherapy-combination-demonstrates-superior-survival-in-metastatic-head-and-neck-cancer 2026-05-24T14:24:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ultra-low-dose-immunotherapy-combination-demonstrates-superior-survival-in-metastatic-head-and-neck-cancer 2026-05-24T14:24:27+00:00 hourly 0.9 https://trial.medpath.com/news/fulgent-genetics-reports-60-response-rate-for-fid-007-in-head-and-neck-cancer-phase-2-trial 2026-05-24T14:22:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fulgent-genetics-reports-60-response-rate-for-fid-007-in-head-and-neck-cancer-phase-2-trial 2026-05-24T14:22:33+00:00 hourly 0.9 https://trial.medpath.com/news/alembic-pharmaceuticals-secures-fda-approval-for-generic-levothyroxine-sodium-tablets-in-1-87-billion-market 2026-05-24T14:14:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alembic-pharmaceuticals-secures-fda-approval-for-generic-levothyroxine-sodium-tablets-in-1-87-billion-market 2026-05-24T14:14:06+00:00 hourly 0.9 https://trial.medpath.com/news/galderma-launches-alastin-regenerative-skincare-brand-across-japan-and-asia-pacific-markets 2026-05-24T14:08:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galderma-launches-alastin-regenerative-skincare-brand-across-japan-and-asia-pacific-markets 2026-05-24T14:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/venus-remedies-secures-first-global-approval-for-plerixafor-in-saudi-arabia 2026-05-24T14:00:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/venus-remedies-secures-first-global-approval-for-plerixafor-in-saudi-arabia 2026-05-24T14:00:01+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-mrna-vaccine-shows-promise-against-three-ebola-virus-strains-in-preclinical-studies 2026-05-24T13:50:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-mrna-vaccine-shows-promise-against-three-ebola-virus-strains-in-preclinical-studies 2026-05-24T13:50:02+00:00 hourly 0.9 https://trial.medpath.com/news/akari-reports-breakthrough-preclinical-data-for-aktx-101-in-kras-mutated-pancreatic-cancer-stock-surges-50 2026-05-24T13:46:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akari-reports-breakthrough-preclinical-data-for-aktx-101-in-kras-mutated-pancreatic-cancer-stock-surges-50 2026-05-24T13:46:11+00:00 hourly 0.9 https://trial.medpath.com/news/bundibugyo-ebola-outbreak-in-drc-and-uganda-declared-public-health-emergency-of-international-concern 2026-05-24T13:46:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bundibugyo-ebola-outbreak-in-drc-and-uganda-declared-public-health-emergency-of-international-concern 2026-05-24T13:46:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-first-ever-approval-for-hepatitis-delta-treatment-with-gilead-s-hepcludex 2026-05-24T13:44:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-first-ever-approval-for-hepatitis-delta-treatment-with-gilead-s-hepcludex 2026-05-24T13:44:08+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-prescription-to-otc-switch-for-adapalene-benzoyl-peroxide-acne-gel 2026-05-24T13:41:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-prescription-to-otc-switch-for-adapalene-benzoyl-peroxide-acne-gel 2026-05-24T13:41:48+00:00 hourly 0.9 https://trial.medpath.com/news/ema-grants-conditional-approval-for-vijoice-first-treatment-for-rare-pik3ca-related-overgrowth-disorders 2026-05-22T19:17:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-grants-conditional-approval-for-vijoice-first-treatment-for-rare-pik3ca-related-overgrowth-disorders 2026-05-22T19:17:01+00:00 hourly 0.9 https://trial.medpath.com/news/vitrafy-s-no-wash-frozen-platelet-technology-achieves-94-recovery-rate-in-us-army-validation-study 2026-05-22T19:15:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vitrafy-s-no-wash-frozen-platelet-technology-achieves-94-recovery-rate-in-us-army-validation-study 2026-05-22T19:15:01+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-accelerates-velzatinib-phase-iii-trial-following-promising-first-line-gist-results 2026-05-22T19:12:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-accelerates-velzatinib-phase-iii-trial-following-promising-first-line-gist-results 2026-05-22T19:12:35+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-foundationone-cdx-as-companion-diagnostic-for-tepotinib-in-met-exon-14-positive-nsclc 2026-05-22T19:01:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-foundationone-cdx-as-companion-diagnostic-for-tepotinib-in-met-exon-14-positive-nsclc 2026-05-22T19:01:38+00:00 hourly 0.9 https://trial.medpath.com/news/genentech-s-astegolimab-copd-program-highlights-critical-trial-design-flaws-in-phase-3-confirmatory-studies 2026-05-22T18:58:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genentech-s-astegolimab-copd-program-highlights-critical-trial-design-flaws-in-phase-3-confirmatory-studies 2026-05-22T18:58:33+00:00 hourly 0.9 https://trial.medpath.com/news/lupeng-pharmaceutical-s-fourth-generation-btk-inhibitor-rocbrutinib-approved-in-china-for-r-r-mcl-global-phase-3-rocket-cll-trial-underway 2026-05-22T18:55:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupeng-pharmaceutical-s-fourth-generation-btk-inhibitor-rocbrutinib-approved-in-china-for-r-r-mcl-global-phase-3-rocket-cll-trial-underway 2026-05-22T18:55:10+00:00 hourly 0.9 https://trial.medpath.com/news/taimed-biologics-completes-phase-2b-enrollment-for-tmb-365-380-hiv-therapy-ahead-of-schedule 2026-05-22T18:53:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taimed-biologics-completes-phase-2b-enrollment-for-tmb-365-380-hiv-therapy-ahead-of-schedule 2026-05-22T18:53:03+00:00 hourly 0.9 https://trial.medpath.com/news/nuance-pharma-receives-nmpa-clearance-for-actair-r-phase-iii-trial-in-china 2026-05-22T18:48:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuance-pharma-receives-nmpa-clearance-for-actair-r-phase-iii-trial-in-china 2026-05-22T18:48:41+00:00 hourly 0.9 https://trial.medpath.com/news/trivarx-partners-with-beyond-drug-development-to-advance-novel-mri-based-cancer-imaging-technology 2026-05-22T18:48:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trivarx-partners-with-beyond-drug-development-to-advance-novel-mri-based-cancer-imaging-technology 2026-05-22T18:48:16+00:00 hourly 0.9 https://trial.medpath.com/news/858-therapeutics-parg-inhibitor-etx-19477-shows-57-orr-in-brca-mutated-ovarian-and-breast-cancer-earns-fda-fast-track-designation 2026-05-22T18:47:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/858-therapeutics-parg-inhibitor-etx-19477-shows-57-orr-in-brca-mutated-ovarian-and-breast-cancer-earns-fda-fast-track-designation 2026-05-22T18:47:46+00:00 hourly 0.9 https://trial.medpath.com/news/beta-bionics-targets-q2-2027-launch-for-mint-patch-pump-to-challenge-insulet-s-market-dominance 2026-05-22T18:42:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beta-bionics-targets-q2-2027-launch-for-mint-patch-pump-to-challenge-insulet-s-market-dominance 2026-05-22T18:42:06+00:00 hourly 0.9 https://trial.medpath.com/news/phase-iii-trial-shows-structured-yoga-program-significantly-reduces-mood-disturbance-anxiety-fatigue-and-insomnia-in-cancer-survivors 2026-05-22T18:37:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-iii-trial-shows-structured-yoga-program-significantly-reduces-mood-disturbance-anxiety-fatigue-and-insomnia-in-cancer-survivors 2026-05-22T18:37:32+00:00 hourly 0.9 https://trial.medpath.com/news/regenxbio-and-abbvie-dose-first-patient-in-phase-iib-iii-naavigate-trial-of-one-time-gene-therapy-sura-vec-for-diabetic-retinopathy 2026-05-22T18:35:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regenxbio-and-abbvie-dose-first-patient-in-phase-iib-iii-naavigate-trial-of-one-time-gene-therapy-sura-vec-for-diabetic-retinopathy 2026-05-22T18:35:22+00:00 hourly 0.9 https://trial.medpath.com/news/ingenia-therapeutics-receives-krx-approval-for-ipo-as-tie2-targeted-therapies-advance-to-phase-3 2026-05-22T18:31:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ingenia-therapeutics-receives-krx-approval-for-ipo-as-tie2-targeted-therapies-advance-to-phase-3 2026-05-22T18:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/servier-to-present-long-term-voranigo-data-and-novel-adc-results-at-asco-2026 2026-05-22T18:30:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/servier-to-present-long-term-voranigo-data-and-novel-adc-results-at-asco-2026 2026-05-22T18:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/novel-car-t-and-verdinexor-combination-therapy-enters-canine-trial-for-pediatric-brain-cancer-treatment 2026-05-22T18:29:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-car-t-and-verdinexor-combination-therapy-enters-canine-trial-for-pediatric-brain-cancer-treatment 2026-05-22T18:29:32+00:00 hourly 0.9 https://trial.medpath.com/news/genfit-reports-strong-q1-2026-revenue-growth-driven-by-iqirvo-royalties-advances-pipeline-across-liver-disease-portfolio 2026-05-22T18:24:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genfit-reports-strong-q1-2026-revenue-growth-driven-by-iqirvo-royalties-advances-pipeline-across-liver-disease-portfolio 2026-05-22T18:24:06+00:00 hourly 0.9 https://trial.medpath.com/news/manchester-biotech-imperagen-raises-ps5m-to-advance-quantum-ai-enzyme-engineering-platform 2026-05-22T18:18:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/manchester-biotech-imperagen-raises-ps5m-to-advance-quantum-ai-enzyme-engineering-platform 2026-05-22T18:18:55+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-car-t-therapy-faces-persistent-logistical-barriers-in-large-b-cell-lymphoma-treatment 2026-05-22T18:17:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-car-t-therapy-faces-persistent-logistical-barriers-in-large-b-cell-lymphoma-treatment 2026-05-22T18:17:21+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-advances-two-major-clinical-programs-in-critical-care-and-cardiovascular-disease 2026-05-22T18:16:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-advances-two-major-clinical-programs-in-critical-care-and-cardiovascular-disease 2026-05-22T18:16:08+00:00 hourly 0.9 https://trial.medpath.com/news/daraxonrasib-doubles-overall-survival-in-metastatic-pancreatic-cancer-highlighted-at-asco-2025 2026-05-22T18:13:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daraxonrasib-doubles-overall-survival-in-metastatic-pancreatic-cancer-highlighted-at-asco-2025 2026-05-22T18:13:04+00:00 hourly 0.9 https://trial.medpath.com/news/oddifact-secures-european-orphan-drug-designation-for-infliximab-in-kawasaki-disease 2026-05-22T18:12:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oddifact-secures-european-orphan-drug-designation-for-infliximab-in-kawasaki-disease 2026-05-22T18:12:43+00:00 hourly 0.9 https://trial.medpath.com/news/outcomes4me-acquires-ai-powered-platforms-to-enhance-cancer-patient-access-to-clinical-trials 2026-05-22T18:11:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/outcomes4me-acquires-ai-powered-platforms-to-enhance-cancer-patient-access-to-clinical-trials 2026-05-22T18:11:54+00:00 hourly 0.9 https://trial.medpath.com/news/massive-bio-and-beekeeperai-deploy-privacy-preserving-ai-to-expand-cancer-trial-access-in-underserved-communities 2026-05-22T18:10:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/massive-bio-and-beekeeperai-deploy-privacy-preserving-ai-to-expand-cancer-trial-access-in-underserved-communities 2026-05-22T18:10:13+00:00 hourly 0.9 https://trial.medpath.com/news/grundium-acquires-visiopharm-to-create-integrated-ai-driven-precision-pathology-platform 2026-05-22T18:06:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grundium-acquires-visiopharm-to-create-integrated-ai-driven-precision-pathology-platform 2026-05-22T18:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/liminatus-pharma-to-acquire-innocsai-in-320-million-deal-gaining-next-generation-car-t-pipeline-for-hematologic-and-solid-tumors 2026-05-22T18:01:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liminatus-pharma-to-acquire-innocsai-in-320-million-deal-gaining-next-generation-car-t-pipeline-for-hematologic-and-solid-tumors 2026-05-22T18:01:45+00:00 hourly 0.9 https://trial.medpath.com/news/amr-bio-launches-with-phase-iii-ready-antimicrobial-xf-73-to-combat-post-surgical-infections 2026-05-22T17:53:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amr-bio-launches-with-phase-iii-ready-antimicrobial-xf-73-to-combat-post-surgical-infections 2026-05-22T17:53:41+00:00 hourly 0.9 https://trial.medpath.com/news/remote-blood-sampling-technology-shows-promise-for-alzheimer-s-disease-biomarker-testing 2026-05-22T17:47:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/remote-blood-sampling-technology-shows-promise-for-alzheimer-s-disease-biomarker-testing 2026-05-22T17:47:49+00:00 hourly 0.9 https://trial.medpath.com/news/concept-life-sciences-and-openbench-launch-ai-driven-success-based-drug-discovery-partnership 2026-05-22T17:46:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/concept-life-sciences-and-openbench-launch-ai-driven-success-based-drug-discovery-partnership 2026-05-22T17:46:52+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-sintilimab-fruquintinib-combination-for-advanced-renal-cell-carcinoma 2026-05-22T17:45:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-sintilimab-fruquintinib-combination-for-advanced-renal-cell-carcinoma 2026-05-22T17:45:23+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-acquires-spr-therapeutics-for-650m-to-expand-pain-management-portfolio 2026-05-22T17:43:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-acquires-spr-therapeutics-for-650m-to-expand-pain-management-portfolio 2026-05-22T17:43:38+00:00 hourly 0.9 https://trial.medpath.com/news/inhibrx-reports-positive-phase-1-2-data-for-ozekibart-in-colorectal-cancer-plans-fda-filing-for-chondrosarcoma 2026-05-22T17:41:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inhibrx-reports-positive-phase-1-2-data-for-ozekibart-in-colorectal-cancer-plans-fda-filing-for-chondrosarcoma 2026-05-22T17:41:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-rare-pediatric-disease-and-orphan-drug-designations-to-fl118-for-osteosarcoma-treatment 2026-05-22T17:40:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-rare-pediatric-disease-and-orphan-drug-designations-to-fl118-for-osteosarcoma-treatment 2026-05-22T17:40:36+00:00 hourly 0.9 https://trial.medpath.com/news/grey-matters-takes-delivery-of-first-brain-dedicated-pet-scanner-for-novascan-neuroimaging-clinic-in-florida 2026-05-22T17:34:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grey-matters-takes-delivery-of-first-brain-dedicated-pet-scanner-for-novascan-neuroimaging-clinic-in-florida 2026-05-22T17:34:33+00:00 hourly 0.9 https://trial.medpath.com/news/insphero-acquires-phenovista-biosciences-to-strengthen-3d-drug-testing-platform 2026-05-22T17:33:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insphero-acquires-phenovista-biosciences-to-strengthen-3d-drug-testing-platform 2026-05-22T17:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/recode-therapeutics-achieves-first-clinical-proof-of-mrna-therapy-activity-in-primary-ciliary-dyskinesia 2026-05-22T17:32:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recode-therapeutics-achieves-first-clinical-proof-of-mrna-therapy-activity-in-primary-ciliary-dyskinesia 2026-05-22T17:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/ryvu-therapeutics-advances-small-molecule-oncology-pipeline-with-european-investment-bank-financing-and-partnership-strategy 2026-05-22T17:28:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ryvu-therapeutics-advances-small-molecule-oncology-pipeline-with-european-investment-bank-financing-and-partnership-strategy 2026-05-22T17:28:38+00:00 hourly 0.9 https://trial.medpath.com/news/histosonics-edison-histotripsy-system-earns-taiwan-fda-approval-for-non-invasive-liver-tumor-treatment 2026-05-22T17:25:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/histosonics-edison-histotripsy-system-earns-taiwan-fda-approval-for-non-invasive-liver-tumor-treatment 2026-05-22T17:25:01+00:00 hourly 0.9 https://trial.medpath.com/news/sarepta-faces-mixed-results-in-patent-challenges-against-genzyme-s-gene-therapy-analytical-methods 2026-05-22T17:17:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarepta-faces-mixed-results-in-patent-challenges-against-genzyme-s-gene-therapy-analytical-methods 2026-05-22T17:17:27+00:00 hourly 0.9 https://trial.medpath.com/news/ichnos-glenmark-innovation-unveils-first-in-class-multispecific-cancer-drug-isb-2301-for-solid-tumors 2026-05-22T17:15:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ichnos-glenmark-innovation-unveils-first-in-class-multispecific-cancer-drug-isb-2301-for-solid-tumors 2026-05-22T17:15:03+00:00 hourly 0.9 https://trial.medpath.com/news/in-utero-gene-therapy-approaches-first-fda-trial-after-25-years-of-development 2026-05-22T17:12:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/in-utero-gene-therapy-approaches-first-fda-trial-after-25-years-of-development 2026-05-22T17:12:24+00:00 hourly 0.9 https://trial.medpath.com/news/qihan-biotech-receives-fda-ind-clearance-for-qt-019c-universal-car-t-therapy-targeting-autoimmune-diseases 2026-05-22T17:10:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qihan-biotech-receives-fda-ind-clearance-for-qt-019c-universal-car-t-therapy-targeting-autoimmune-diseases 2026-05-22T17:10:27+00:00 hourly 0.9 https://trial.medpath.com/news/oorja-bio-launches-with-30m-to-develop-novel-regenerative-therapy-for-idiopathic-pulmonary-fibrosis 2026-05-22T17:03:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oorja-bio-launches-with-30m-to-develop-novel-regenerative-therapy-for-idiopathic-pulmonary-fibrosis 2026-05-22T17:03:47+00:00 hourly 0.9 https://trial.medpath.com/news/23andme-partners-with-healthex-to-launch-ai-powered-health-summary-integrating-genetic-and-medical-data 2026-05-22T17:03:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/23andme-partners-with-healthex-to-launch-ai-powered-health-summary-integrating-genetic-and-medical-data 2026-05-22T17:03:31+00:00 hourly 0.9 https://trial.medpath.com/news/flow-pharma-receives-patent-allowance-for-universal-ebola-treatment-using-siltuximab 2026-05-22T17:02:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flow-pharma-receives-patent-allowance-for-universal-ebola-treatment-using-siltuximab 2026-05-22T17:02:22+00:00 hourly 0.9 https://trial.medpath.com/news/canadian-researchers-launch-largest-fmt-trial-to-enhance-lung-cancer-immunotherapy 2026-05-22T17:01:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canadian-researchers-launch-largest-fmt-trial-to-enhance-lung-cancer-immunotherapy 2026-05-22T17:01:17+00:00 hourly 0.9 https://trial.medpath.com/news/tocilizumab-shows-promise-as-immunotherapy-for-treatment-resistant-depression-in-pilot-trial 2026-05-22T17:00:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tocilizumab-shows-promise-as-immunotherapy-for-treatment-resistant-depression-in-pilot-trial 2026-05-22T17:00:58+00:00 hourly 0.9 https://trial.medpath.com/news/ai-powered-speech-assessment-detects-alzheimer-s-pathology-through-automated-phone-calls 2026-05-22T16:59:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-powered-speech-assessment-detects-alzheimer-s-pathology-through-automated-phone-calls 2026-05-22T16:59:59+00:00 hourly 0.9 https://trial.medpath.com/news/haya-therapeutics-doses-first-patients-in-phase-1-trial-of-htx-001-for-cardiac-fibrosis 2026-05-22T16:59:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/haya-therapeutics-doses-first-patients-in-phase-1-trial-of-htx-001-for-cardiac-fibrosis 2026-05-22T16:59:38+00:00 hourly 0.9 https://trial.medpath.com/news/collaborative-drug-discovery-partners-with-eli-lilly-to-integrate-ai-ml-models-into-cdd-vault-platform 2026-05-22T16:56:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/collaborative-drug-discovery-partners-with-eli-lilly-to-integrate-ai-ml-models-into-cdd-vault-platform 2026-05-22T16:56:07+00:00 hourly 0.9 https://trial.medpath.com/news/continuity-biosciences-initiates-first-in-human-trial-of-iontophoretic-drug-delivery-platform-for-pancreatic-cancer 2026-05-22T16:55:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/continuity-biosciences-initiates-first-in-human-trial-of-iontophoretic-drug-delivery-platform-for-pancreatic-cancer 2026-05-22T16:55:20+00:00 hourly 0.9 https://trial.medpath.com/news/sarah-cannon-research-institute-partners-with-pfizer-to-accelerate-community-based-oncology-trials 2026-05-22T16:52:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarah-cannon-research-institute-partners-with-pfizer-to-accelerate-community-based-oncology-trials 2026-05-22T16:52:41+00:00 hourly 0.9 https://trial.medpath.com/news/from-dysbiosis-to-precision-medicine-targeting-the-microbial-metabolic-axis-in-ibd-management 2026-05-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/from-dysbiosis-to-precision-medicine-targeting-the-microbial-metabolic-axis-in-ibd-management 2026-05-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/oura-files-confidentially-for-us-ipo-as-smart-ring-health-platform-targets-2-billion-revenue 2026-05-21T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oura-files-confidentially-for-us-ipo-as-smart-ring-health-platform-targets-2-billion-revenue 2026-05-21T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/surgeon-general-advisory-warns-excessive-screen-use-is-a-top-public-health-threat-for-children-and-adolescents 2026-05-21T16:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/surgeon-general-advisory-warns-excessive-screen-use-is-a-top-public-health-threat-for-children-and-adolescents 2026-05-21T16:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/antag-therapeutics-first-in-class-gipr-antagonist-at7687-shows-promising-phase-1-results-and-preclinical-combination-data-at-ada-2026 2026-05-21T11:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antag-therapeutics-first-in-class-gipr-antagonist-at7687-shows-promising-phase-1-results-and-preclinical-combination-data-at-ada-2026 2026-05-21T11:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/ayvakit-avapritinib-high-response-rates-in-rare-cancers-and-mastocytosis-with-critical-safety-monitoring-requirements 2026-05-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ayvakit-avapritinib-high-response-rates-in-rare-cancers-and-mastocytosis-with-critical-safety-monitoring-requirements 2026-05-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/one-biosciences-secures-pscc-boost-funding-to-develop-first-single-cell-assay-for-adc-therapies-in-oncology 2026-05-20T09:59:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/one-biosciences-secures-pscc-boost-funding-to-develop-first-single-cell-assay-for-adc-therapies-in-oncology 2026-05-20T09:59:23+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-s-dysport-shows-superior-duration-over-botox-in-first-head-to-head-spasticity-trial 2026-05-20T09:31:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ipsen-s-dysport-shows-superior-duration-over-botox-in-first-head-to-head-spasticity-trial 2026-05-20T09:31:54+00:00 hourly 0.9 https://trial.medpath.com/news/matter-bio-files-first-ind-for-listeria-based-immunotherapy-targeting-pancreatic-cancer 2026-05-20T09:30:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/matter-bio-files-first-ind-for-listeria-based-immunotherapy-targeting-pancreatic-cancer 2026-05-20T09:30:17+00:00 hourly 0.9 https://trial.medpath.com/news/dynamx-bioadaptor-shows-88-reduction-in-cardiovascular-death-compared-to-drug-eluting-stents-in-four-year-trial 2026-05-20T09:19:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dynamx-bioadaptor-shows-88-reduction-in-cardiovascular-death-compared-to-drug-eluting-stents-in-four-year-trial 2026-05-20T09:19:02+00:00 hourly 0.9 https://trial.medpath.com/news/mabylon-advances-my006-peanut-allergy-treatment-to-phase-ib-following-positive-safety-data 2026-05-20T09:08:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mabylon-advances-my006-peanut-allergy-treatment-to-phase-ib-following-positive-safety-data 2026-05-20T09:08:51+00:00 hourly 0.9 https://trial.medpath.com/news/century-health-raises-5m-seed-round-as-ai-platform-achieves-97-accuracy-in-clinical-data-abstraction 2026-05-20T09:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/century-health-raises-5m-seed-round-as-ai-platform-achieves-97-accuracy-in-clinical-data-abstraction 2026-05-20T09:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/oorja-bio-launches-with-30m-series-a-to-advance-novel-ipf-therapy-orj-001 2026-05-20T09:06:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oorja-bio-launches-with-30m-series-a-to-advance-novel-ipf-therapy-orj-001 2026-05-20T09:06:09+00:00 hourly 0.9 https://trial.medpath.com/news/fujifilm-cellular-dynamics-opens-200-million-ipsc-manufacturing-facility-to-quadruple-production-capacity 2026-05-20T09:04:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fujifilm-cellular-dynamics-opens-200-million-ipsc-manufacturing-facility-to-quadruple-production-capacity 2026-05-20T09:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-s-glaucoma-drug-pdp-716-receives-fda-complete-response-letter-due-to-manufacturing-facility-issues 2026-05-20T09:00:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-s-glaucoma-drug-pdp-716-receives-fda-complete-response-letter-due-to-manufacturing-facility-issues 2026-05-20T09:00:07+00:00 hourly 0.9 https://trial.medpath.com/news/mentari-therapeutics-goes-public-through-421m-reverse-merger-to-advance-novel-pacap-targeting-migraine-therapies 2026-05-20T08:59:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mentari-therapeutics-goes-public-through-421m-reverse-merger-to-advance-novel-pacap-targeting-migraine-therapies 2026-05-20T08:59:48+00:00 hourly 0.9 https://trial.medpath.com/news/risen-pharma-initiates-phase-2-trial-of-rp902-for-alzheimer-s-disease-in-china 2026-05-20T08:55:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/risen-pharma-initiates-phase-2-trial-of-rp902-for-alzheimer-s-disease-in-china 2026-05-20T08:55:28+00:00 hourly 0.9 https://trial.medpath.com/news/dropshot-therapeutics-advances-renal-disease-program-to-clinical-stage-using-etherna-s-mrna-platform 2026-05-20T08:53:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dropshot-therapeutics-advances-renal-disease-program-to-clinical-stage-using-etherna-s-mrna-platform 2026-05-20T08:53:39+00:00 hourly 0.9 https://trial.medpath.com/news/blank-bio-secures-7-2m-seed-funding-and-pacbio-partnership-to-advance-rna-foundation-models-for-precision-oncology 2026-05-20T08:51:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blank-bio-secures-7-2m-seed-funding-and-pacbio-partnership-to-advance-rna-foundation-models-for-precision-oncology 2026-05-20T08:51:39+00:00 hourly 0.9 https://trial.medpath.com/news/mekanistic-therapeutics-receives-fda-clearance-for-first-in-class-dual-pi3k-egfr-inhibitor-mtx-531 2026-05-20T08:51:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mekanistic-therapeutics-receives-fda-clearance-for-first-in-class-dual-pi3k-egfr-inhibitor-mtx-531 2026-05-20T08:51:29+00:00 hourly 0.9 https://trial.medpath.com/news/matisse-pharmaceuticals-receives-fda-ind-clearance-for-novel-sepsis-treatment-isupartob-sodium 2026-05-20T08:51:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/matisse-pharmaceuticals-receives-fda-ind-clearance-for-novel-sepsis-treatment-isupartob-sodium 2026-05-20T08:51:18+00:00 hourly 0.9 https://trial.medpath.com/news/exelixis-partners-with-merck-for-phase-3-colorectal-cancer-trial-combining-zanzalintinib-with-keytruda 2026-05-20T08:50:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exelixis-partners-with-merck-for-phase-3-colorectal-cancer-trial-combining-zanzalintinib-with-keytruda 2026-05-20T08:50:42+00:00 hourly 0.9 https://trial.medpath.com/news/accro-bioscience-secures-50m-series-c-to-advance-ripk2-inhibitor-ac-101-for-ulcerative-colitis 2026-05-20T08:47:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accro-bioscience-secures-50m-series-c-to-advance-ripk2-inhibitor-ac-101-for-ulcerative-colitis 2026-05-20T08:47:22+00:00 hourly 0.9 https://trial.medpath.com/news/sandboxaq-to-bring-physics-grounded-drug-discovery-models-to-google-cloud-marketplace 2026-05-20T08:47:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sandboxaq-to-bring-physics-grounded-drug-discovery-models-to-google-cloud-marketplace 2026-05-20T08:47:05+00:00 hourly 0.9 https://trial.medpath.com/news/proencia-biotechnology-secures-pre-seed-funding-to-advance-novel-periodontal-disease-treatment-pipeline 2026-05-20T08:45:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proencia-biotechnology-secures-pre-seed-funding-to-advance-novel-periodontal-disease-treatment-pipeline 2026-05-20T08:45:52+00:00 hourly 0.9 https://trial.medpath.com/news/cyclana-bio-launches-500-patient-study-to-decode-endometriosis-mechanisms-using-novel-tissue-based-approach 2026-05-20T08:44:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cyclana-bio-launches-500-patient-study-to-decode-endometriosis-mechanisms-using-novel-tissue-based-approach 2026-05-20T08:44:42+00:00 hourly 0.9 https://trial.medpath.com/news/neurodiscovery-ai-launches-neuroterminal-platform-to-accelerate-neurological-clinical-trial-recruitment 2026-05-20T08:44:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurodiscovery-ai-launches-neuroterminal-platform-to-accelerate-neurological-clinical-trial-recruitment 2026-05-20T08:44:24+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-launches-pivotal-phase-2-3-revival-trial-of-pivekimab-sunirine-in-first-line-aml-expands-into-pediatric-setting 2026-05-20T08:43:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-launches-pivotal-phase-2-3-revival-trial-of-pivekimab-sunirine-in-first-line-aml-expands-into-pediatric-setting 2026-05-20T08:43:11+00:00 hourly 0.9 https://trial.medpath.com/news/hephaistos-pharma-appoints-stephan-braun-as-chief-medical-officer-to-advance-tlr4-agonist-hepha440-toward-clinical-trials 2026-05-20T08:39:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hephaistos-pharma-appoints-stephan-braun-as-chief-medical-officer-to-advance-tlr4-agonist-hepha440-toward-clinical-trials 2026-05-20T08:39:51+00:00 hourly 0.9 https://trial.medpath.com/news/cullinan-therapeutics-receives-fda-orphan-drug-designation-for-novel-flt3xcd3-t-cell-engager-cln-049-in-relapsed-refractory-aml 2026-05-20T08:38:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cullinan-therapeutics-receives-fda-orphan-drug-designation-for-novel-flt3xcd3-t-cell-engager-cln-049-in-relapsed-refractory-aml 2026-05-20T08:38:18+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-s-seismiq-4ce-coronary-lithotripsy-catheter-meets-primary-endpoints-in-pivotal-fracture-trial 2026-05-20T08:37:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boston-scientific-s-seismiq-4ce-coronary-lithotripsy-catheter-meets-primary-endpoints-in-pivotal-fracture-trial 2026-05-20T08:37:27+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-experimental-alpha-1-antitrypsin-therapy-outperforms-standard-care-in-phase-3-trial 2026-05-20T08:07:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-s-experimental-alpha-1-antitrypsin-therapy-outperforms-standard-care-in-phase-3-trial 2026-05-20T08:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-faces-885-million-antitrust-verdict-for-delaying-generic-constipation-drug-amitiza 2026-05-20T07:57:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-faces-885-million-antitrust-verdict-for-delaying-generic-constipation-drug-amitiza 2026-05-20T07:57:10+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-efdoralprin-alfa-demonstrates-superior-efficacy-over-standard-care-in-alpha-1-antitrypsin-deficiency-phase-2-trial 2026-05-20T07:55:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-s-efdoralprin-alfa-demonstrates-superior-efficacy-over-standard-care-in-alpha-1-antitrypsin-deficiency-phase-2-trial 2026-05-20T07:55:18+00:00 hourly 0.9 https://trial.medpath.com/news/vir-biotechnology-to-present-96-week-data-from-phase-2-solstice-trial-for-chronic-hepatitis-delta-at-easl-congress-2026 2026-05-20T07:53:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vir-biotechnology-to-present-96-week-data-from-phase-2-solstice-trial-for-chronic-hepatitis-delta-at-easl-congress-2026 2026-05-20T07:53:35+00:00 hourly 0.9 https://trial.medpath.com/news/ms-pharma-secures-strategic-investment-from-olayan-financing-company-to-accelerate-mena-biosimilars-expansion 2026-05-20T07:47:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ms-pharma-secures-strategic-investment-from-olayan-financing-company-to-accelerate-mena-biosimilars-expansion 2026-05-20T07:47:35+00:00 hourly 0.9 https://trial.medpath.com/news/mesenchymal-stem-cell-therapy-shows-promise-for-rare-butterfly-skin-disease-in-spanish-clinical-trial 2026-05-20T07:47:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mesenchymal-stem-cell-therapy-shows-promise-for-rare-butterfly-skin-disease-in-spanish-clinical-trial 2026-05-20T07:47:26+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-confirms-tezepelumab-efficacy-in-underrepresented-severe-asthma-populations 2026-05-20T07:45:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-confirms-tezepelumab-efficacy-in-underrepresented-severe-asthma-populations 2026-05-20T07:45:07+00:00 hourly 0.9 https://trial.medpath.com/news/roche-partners-with-un-backed-group-to-expand-global-access-to-influenza-drug-xofluza 2026-05-20T07:42:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-partners-with-un-backed-group-to-expand-global-access-to-influenza-drug-xofluza 2026-05-20T07:42:01+00:00 hourly 0.9 https://trial.medpath.com/news/quince-therapeutics-reports-positive-phase-2a-results-for-lam-001-in-pulmonary-hypertension 2026-05-20T07:40:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quince-therapeutics-reports-positive-phase-2a-results-for-lam-001-in-pulmonary-hypertension 2026-05-20T07:40:07+00:00 hourly 0.9 https://trial.medpath.com/news/mavodelpar-shows-promise-in-phase-1-trial-for-primary-mitochondrial-myopathy 2026-05-20T07:38:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mavodelpar-shows-promise-in-phase-1-trial-for-primary-mitochondrial-myopathy 2026-05-20T07:38:18+00:00 hourly 0.9 https://trial.medpath.com/news/12-year-old-becomes-first-indiana-patient-to-receive-fda-approved-gene-therapy-for-beta-thalassemia 2026-05-20T07:37:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/12-year-old-becomes-first-indiana-patient-to-receive-fda-approved-gene-therapy-for-beta-thalassemia 2026-05-20T07:37:39+00:00 hourly 0.9 https://trial.medpath.com/news/hedge-fund-adar1-capital-invests-37-million-in-crinetics-pharmaceuticals-following-palsonify-launch 2026-05-20T07:37:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hedge-fund-adar1-capital-invests-37-million-in-crinetics-pharmaceuticals-following-palsonify-launch 2026-05-20T07:37:28+00:00 hourly 0.9 https://trial.medpath.com/news/sino-biological-launches-xpressmax-cell-free-protein-synthesis-kit-for-ai-driven-antibody-discovery 2026-05-20T07:35:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sino-biological-launches-xpressmax-cell-free-protein-synthesis-kit-for-ai-driven-antibody-discovery 2026-05-20T07:35:44+00:00 hourly 0.9 https://trial.medpath.com/news/illuminare-biotechnologies-advances-nerve-visualization-drug-illuminare-1-to-phase-ii-trial-following-successful-phase-i-results 2026-05-20T07:34:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/illuminare-biotechnologies-advances-nerve-visualization-drug-illuminare-1-to-phase-ii-trial-following-successful-phase-i-results 2026-05-20T07:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/bracco-s-vueject-receives-fda-510-k-clearance-and-health-canada-authorization-as-first-dedicated-ultrasound-contrast-delivery-system-for-cardiology-imaging 2026-05-20T07:32:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bracco-s-vueject-receives-fda-510-k-clearance-and-health-canada-authorization-as-first-dedicated-ultrasound-contrast-delivery-system-for-cardiology-imaging 2026-05-20T07:32:54+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-invests-1-5-billion-in-mirus-for-revolutionary-nickel-free-tavr-technology 2026-05-20T07:32:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boston-scientific-invests-1-5-billion-in-mirus-for-revolutionary-nickel-free-tavr-technology 2026-05-20T07:32:47+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-azd3470-shows-promise-in-first-in-human-trial-for-relapsed-refractory-hodgkin-lymphoma 2026-05-20T07:32:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-azd3470-shows-promise-in-first-in-human-trial-for-relapsed-refractory-hodgkin-lymphoma 2026-05-20T07:32:14+00:00 hourly 0.9 https://trial.medpath.com/news/who-prepares-clinical-trial-of-experimental-ebola-treatments-as-bundibugyo-outbreak-spreads-across-central-africa 2026-05-20T07:32:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-prepares-clinical-trial-of-experimental-ebola-treatments-as-bundibugyo-outbreak-spreads-across-central-africa 2026-05-20T07:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/quince-therapeutics-acquires-orphai-for-187m-to-advance-inhaled-rapamycin-pipeline-for-rare-pulmonary-diseases 2026-05-20T07:28:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quince-therapeutics-acquires-orphai-for-187m-to-advance-inhaled-rapamycin-pipeline-for-rare-pulmonary-diseases 2026-05-20T07:28:40+00:00 hourly 0.9 https://trial.medpath.com/news/tricelx-files-first-cell-therapy-ind-for-chronic-traumatic-encephalopathy-with-dual-fda-designations 2026-05-20T07:18:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tricelx-files-first-cell-therapy-ind-for-chronic-traumatic-encephalopathy-with-dual-fda-designations 2026-05-20T07:18:07+00:00 hourly 0.9 https://trial.medpath.com/news/oral-pv-10-shows-promising-anti-tumor-activity-in-preclinical-bladder-cancer-study 2026-05-20T07:16:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oral-pv-10-shows-promising-anti-tumor-activity-in-preclinical-bladder-cancer-study 2026-05-20T07:16:41+00:00 hourly 0.9 https://trial.medpath.com/news/uk-mhra-approves-vyjuvek-gene-therapy-for-dystrophic-epidermolysis-bullosa-from-birth 2026-05-20T07:15:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-mhra-approves-vyjuvek-gene-therapy-for-dystrophic-epidermolysis-bullosa-from-birth 2026-05-20T07:15:22+00:00 hourly 0.9 https://trial.medpath.com/news/children-s-mercy-partners-with-basepath-health-to-scale-cell-and-gene-therapy-access-for-pediatric-patients 2026-05-20T07:15:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/children-s-mercy-partners-with-basepath-health-to-scale-cell-and-gene-therapy-access-for-pediatric-patients 2026-05-20T07:15:11+00:00 hourly 0.9 https://trial.medpath.com/news/triveni-bio-initiates-phase-1-trial-of-dual-target-bispecific-antibody-triv-573-for-atopic-dermatitis 2026-05-20T07:11:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/triveni-bio-initiates-phase-1-trial-of-dual-target-bispecific-antibody-triv-573-for-atopic-dermatitis 2026-05-20T07:11:03+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-s-bmn-401-shows-mixed-results-in-phase-3-trial-for-rare-enpp1-deficiency 2026-05-20T07:10:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarin-s-bmn-401-shows-mixed-results-in-phase-3-trial-for-rare-enpp1-deficiency 2026-05-20T07:10:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-ver-01-first-in-class-cannabis-based-treatment-for-chronic-low-back-pain 2026-05-20T07:09:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-ver-01-first-in-class-cannabis-based-treatment-for-chronic-low-back-pain 2026-05-20T07:09:27+00:00 hourly 0.9 https://trial.medpath.com/news/prilenia-withdraws-european-application-for-huntington-s-disease-drug-pridopidine-after-regulatory-rejection 2026-05-20T07:06:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prilenia-withdraws-european-application-for-huntington-s-disease-drug-pridopidine-after-regulatory-rejection 2026-05-20T07:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/piramal-pharma-solutions-partners-with-botanix-to-secure-supply-chain-for-fda-approved-hyperhidrosis-treatment-sofdra 2026-05-20T07:06:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/piramal-pharma-solutions-partners-with-botanix-to-secure-supply-chain-for-fda-approved-hyperhidrosis-treatment-sofdra 2026-05-20T07:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/elanco-launches-befrena-new-anti-il-31-monoclonal-antibody-for-canine-allergic-dermatitis 2026-05-20T07:06:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elanco-launches-befrena-new-anti-il-31-monoclonal-antibody-for-canine-allergic-dermatitis 2026-05-20T07:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-and-genesis-expand-ai-drug-discovery-partnership-in-120m-deal 2026-05-19T12:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incyte-and-genesis-expand-ai-drug-discovery-partnership-in-120m-deal 2026-05-19T12:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/nice-recommends-blueprint-medicines-ayvakyt-for-advanced-systemic-mastocytosis-on-nhs 2026-05-18T14:04:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-recommends-blueprint-medicines-ayvakyt-for-advanced-systemic-mastocytosis-on-nhs 2026-05-18T14:04:54+00:00 hourly 0.9 https://trial.medpath.com/news/cellogen-therapeutics-secures-2-4m-to-advance-affordable-car-t-cancer-therapies-in-india 2026-05-18T13:15:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellogen-therapeutics-secures-2-4m-to-advance-affordable-car-t-cancer-therapies-in-india 2026-05-18T13:15:53+00:00 hourly 0.9 https://trial.medpath.com/news/vincentage-pharma-s-oral-glp-1-agonist-vct220-achieves-12-weight-loss-in-pivotal-phase-3-trial 2026-05-18T13:13:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vincentage-pharma-s-oral-glp-1-agonist-vct220-achieves-12-weight-loss-in-pivotal-phase-3-trial 2026-05-18T13:13:06+00:00 hourly 0.9 https://trial.medpath.com/news/parsortix-ctc-platform-demonstrates-feasibility-for-adc-target-assessment-in-breast-and-ovarian-cancers 2026-05-18T13:10:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/parsortix-ctc-platform-demonstrates-feasibility-for-adc-target-assessment-in-breast-and-ovarian-cancers 2026-05-18T13:10:57+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-s-alecensa-receives-world-s-first-tumor-agnostic-approval-for-alk-fusion-positive-solid-tumors 2026-05-18T13:07:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chugai-s-alecensa-receives-world-s-first-tumor-agnostic-approval-for-alk-fusion-positive-solid-tumors 2026-05-18T13:07:32+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-secures-orphan-drug-designation-in-japan-for-novel-acth-targeting-antibody-asedebart 2026-05-18T13:06:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lundbeck-secures-orphan-drug-designation-in-japan-for-novel-acth-targeting-antibody-asedebart 2026-05-18T13:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/danish-biotech-alcolase-raises-eur1-5m-to-develop-enzyme-treatment-for-alcohol-intolerance-in-east-asia 2026-05-18T12:59:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/danish-biotech-alcolase-raises-eur1-5m-to-develop-enzyme-treatment-for-alcohol-intolerance-in-east-asia 2026-05-18T12:59:36+00:00 hourly 0.9 https://trial.medpath.com/news/prokarium-s-zh9-shows-91-freedom-from-relapse-in-phase-1-1b-trial-for-non-muscle-invasive-bladder-cancer 2026-05-18T12:59:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prokarium-s-zh9-shows-91-freedom-from-relapse-in-phase-1-1b-trial-for-non-muscle-invasive-bladder-cancer 2026-05-18T12:59:19+00:00 hourly 0.9 https://trial.medpath.com/news/lotte-biologics-expands-manufacturing-partnership-with-ottimo-pharma-for-biparatopic-antibody-development 2026-05-18T12:58:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lotte-biologics-expands-manufacturing-partnership-with-ottimo-pharma-for-biparatopic-antibody-development 2026-05-18T12:58:55+00:00 hourly 0.9 https://trial.medpath.com/news/cosmo-completes-phase-ii-enrollment-for-novel-rifamycin-enema-in-distal-ulcerative-colitis 2026-05-18T12:57:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cosmo-completes-phase-ii-enrollment-for-novel-rifamycin-enema-in-distal-ulcerative-colitis 2026-05-18T12:57:46+00:00 hourly 0.9 https://trial.medpath.com/news/harbour-biomed-s-ai-designed-let003-shows-superior-obesity-treatment-potential-in-preclinical-studies 2026-05-18T12:53:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harbour-biomed-s-ai-designed-let003-shows-superior-obesity-treatment-potential-in-preclinical-studies 2026-05-18T12:53:14+00:00 hourly 0.9 https://trial.medpath.com/news/beigene-and-revolution-medicines-forge-strategic-partnership-to-bring-breakthrough-pancreatic-cancer-therapy-to-asia 2026-05-18T12:47:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beigene-and-revolution-medicines-forge-strategic-partnership-to-bring-breakthrough-pancreatic-cancer-therapy-to-asia 2026-05-18T12:47:38+00:00 hourly 0.9 https://trial.medpath.com/news/stereotactic-ablative-body-radiotherapy-achieves-100-local-control-in-primary-kidney-cancer-fastrack-ii-final-results 2026-05-18T12:46:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stereotactic-ablative-body-radiotherapy-achieves-100-local-control-in-primary-kidney-cancer-fastrack-ii-final-results 2026-05-18T12:46:22+00:00 hourly 0.9 https://trial.medpath.com/news/organabio-acquires-excellos-assets-to-create-bicoastal-cell-therapy-manufacturing-network 2026-05-18T12:29:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/organabio-acquires-excellos-assets-to-create-bicoastal-cell-therapy-manufacturing-network 2026-05-18T12:29:24+00:00 hourly 0.9 https://trial.medpath.com/news/impact-td-registry-reveals-stark-diagnostic-gap-only-23-of-young-adults-with-mood-disorders-and-tardive-dyskinesia-symptoms-receive-formal-diagnosis 2026-05-18T12:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/impact-td-registry-reveals-stark-diagnostic-gap-only-23-of-young-adults-with-mood-disorders-and-tardive-dyskinesia-symptoms-receive-formal-diagnosis 2026-05-18T12:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/precision-neuroscience-harnessing-ai-and-multi-omics-to-bridge-lab-discoveries-and-clinical-solutions-for-neurodegenerative-disorders 2026-05-18T03:39:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-neuroscience-harnessing-ai-and-multi-omics-to-bridge-lab-discoveries-and-clinical-solutions-for-neurodegenerative-disorders 2026-05-18T03:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/merck-s-once-monthly-oral-prep-pill-mk-8527-enters-phase-3-trial-enrolling-high-risk-populations-in-newark 2026-05-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-s-once-monthly-oral-prep-pill-mk-8527-enters-phase-3-trial-enrolling-high-risk-populations-in-newark 2026-05-17T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/select-early-stage-breast-cancer-patients-achieve-complete-response-without-surgery-following-ablative-radiation-and-endocrine-therapy 2026-05-16T22:22:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/select-early-stage-breast-cancer-patients-achieve-complete-response-without-surgery-following-ablative-radiation-and-endocrine-therapy 2026-05-16T22:22:38+00:00 hourly 0.9 https://trial.medpath.com/news/y-mabs-therapeutics-restructures-pipeline-following-fda-rejection-of-neuroblastoma-drug-omburtamab 2026-05-16T22:21:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/y-mabs-therapeutics-restructures-pipeline-following-fda-rejection-of-neuroblastoma-drug-omburtamab 2026-05-16T22:21:05+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-expands-nurtec-odt-migraine-program-with-korean-real-world-study-and-new-tablet-formulation 2026-05-16T22:20:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-expands-nurtec-odt-migraine-program-with-korean-real-world-study-and-new-tablet-formulation 2026-05-16T22:20:58+00:00 hourly 0.9 https://trial.medpath.com/news/jasper-therapeutics-advances-targeted-antibody-conditioning-platform-for-stem-cell-transplants-and-gene-therapies 2026-05-16T22:16:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jasper-therapeutics-advances-targeted-antibody-conditioning-platform-for-stem-cell-transplants-and-gene-therapies 2026-05-16T22:16:03+00:00 hourly 0.9 https://trial.medpath.com/news/xbiotech-launches-phase-ii-trial-of-vilamakitug-for-active-axial-spondyloarthritis-following-fda-clearance 2026-05-16T22:07:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xbiotech-launches-phase-ii-trial-of-vilamakitug-for-active-axial-spondyloarthritis-following-fda-clearance 2026-05-16T22:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/japanese-pharmaceutical-company-warns-against-tavneos-use-after-20-deaths-linked-to-severe-liver-dysfunction 2026-05-16T22:06:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japanese-pharmaceutical-company-warns-against-tavneos-use-after-20-deaths-linked-to-severe-liver-dysfunction 2026-05-16T22:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-s-fianlimab-cemiplimab-combination-misses-primary-endpoint-in-phase-3-melanoma-trial 2026-05-16T21:59:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-s-fianlimab-cemiplimab-combination-misses-primary-endpoint-in-phase-3-melanoma-trial 2026-05-16T21:59:57+00:00 hourly 0.9 https://trial.medpath.com/news/phase-ii-trial-shows-promise-for-pembrolizumab-lenvatinib-combination-in-mucosal-melanoma 2026-05-16T21:58:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-ii-trial-shows-promise-for-pembrolizumab-lenvatinib-combination-in-mucosal-melanoma 2026-05-16T21:58:14+00:00 hourly 0.9 https://trial.medpath.com/news/united-therapeutics-receives-fda-clearance-for-first-human-trial-of-genetically-modified-pig-heart-transplant 2026-05-16T21:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/united-therapeutics-receives-fda-clearance-for-first-human-trial-of-genetically-modified-pig-heart-transplant 2026-05-16T21:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/stem-cell-therapy-shows-promise-for-alzheimer-s-disease-in-combination-trial 2026-05-16T21:49:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stem-cell-therapy-shows-promise-for-alzheimer-s-disease-in-combination-trial 2026-05-16T21:49:40+00:00 hourly 0.9 https://trial.medpath.com/news/kh607-meets-primary-endpoint-in-phase-2b-trial-for-major-depressive-disorder 2026-05-16T21:31:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kh607-meets-primary-endpoint-in-phase-2b-trial-for-major-depressive-disorder 2026-05-16T21:31:46+00:00 hourly 0.9 https://trial.medpath.com/news/favipiravir-shows-50-mortality-reduction-in-first-randomized-lassa-fever-trial-in-four-decades 2026-05-16T21:18:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/favipiravir-shows-50-mortality-reduction-in-first-randomized-lassa-fever-trial-in-four-decades 2026-05-16T21:18:14+00:00 hourly 0.9 https://trial.medpath.com/news/valirx-secures-ps1-16m-funding-to-advance-cancer-therapeutics-and-women-s-health-pipeline 2026-05-16T21:17:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valirx-secures-ps1-16m-funding-to-advance-cancer-therapeutics-and-women-s-health-pipeline 2026-05-16T21:17:49+00:00 hourly 0.9 https://trial.medpath.com/news/akeso-s-ligufalimab-shows-promising-phase-ii-results-in-frontline-aml-treatment 2026-05-16T21:17:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akeso-s-ligufalimab-shows-promising-phase-ii-results-in-frontline-aml-treatment 2026-05-16T21:17:01+00:00 hourly 0.9 https://trial.medpath.com/news/iqirvo-shows-promising-real-world-results-for-primary-biliary-cholangitis-at-easl-2026 2026-05-16T21:12:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iqirvo-shows-promising-real-world-results-for-primary-biliary-cholangitis-at-easl-2026 2026-05-16T21:12:13+00:00 hourly 0.9 https://trial.medpath.com/news/alteogen-receives-korean-approval-for-aflibercept-biosimilar-targeting-growing-retinal-disease-market 2026-05-16T21:10:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alteogen-receives-korean-approval-for-aflibercept-biosimilar-targeting-growing-retinal-disease-market 2026-05-16T21:10:36+00:00 hourly 0.9 https://trial.medpath.com/news/congo-s-17th-ebola-outbreak-bundibugyo-strain-confirmed-as-death-toll-reaches-80 2026-05-15T07:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/congo-s-17th-ebola-outbreak-bundibugyo-strain-confirmed-as-death-toll-reaches-80 2026-05-15T07:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/ninamed-secures-13-75m-to-advance-non-invasive-overactive-bladder-therapy-targeting-550-million-patients 2026-05-15T06:22:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ninamed-secures-13-75m-to-advance-non-invasive-overactive-bladder-therapy-targeting-550-million-patients 2026-05-15T06:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/edap-and-telix-partner-to-advance-precision-prostate-cancer-treatment-through-hifu-psma-pet-integration 2026-05-15T06:15:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/edap-and-telix-partner-to-advance-precision-prostate-cancer-treatment-through-hifu-psma-pet-integration 2026-05-15T06:15:18+00:00 hourly 0.9 https://trial.medpath.com/news/sn-bioscience-initiates-global-phase-1b-2-trial-of-snb-101-for-small-cell-lung-cancer-with-zero-high-grade-diarrhea-events 2026-05-15T06:10:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sn-bioscience-initiates-global-phase-1b-2-trial-of-snb-101-for-small-cell-lung-cancer-with-zero-high-grade-diarrhea-events 2026-05-15T06:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/valion-bio-s-velocity-bioworks-secures-exclusive-license-for-next-generation-nmr-diagnostic-platform 2026-05-15T06:08:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valion-bio-s-velocity-bioworks-secures-exclusive-license-for-next-generation-nmr-diagnostic-platform 2026-05-15T06:08:52+00:00 hourly 0.9 https://trial.medpath.com/news/singapore-launches-clinical-studies-to-evaluate-multi-cancer-early-detection-tests-in-asian-populations 2026-05-15T06:08:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/singapore-launches-clinical-studies-to-evaluate-multi-cancer-early-detection-tests-in-asian-populations 2026-05-15T06:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/massive-bio-and-gell-announce-strategic-partnership-to-advance-ai-driven-precision-oncology-across-latin-america-and-the-united-states 2026-05-15T06:06:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/massive-bio-and-gell-announce-strategic-partnership-to-advance-ai-driven-precision-oncology-across-latin-america-and-the-united-states 2026-05-15T06:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/voxcell-bioinnovation-and-admare-partner-to-validate-bioprinted-cancer-models-for-antibody-therapy-development 2026-05-15T05:58:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/voxcell-bioinnovation-and-admare-partner-to-validate-bioprinted-cancer-models-for-antibody-therapy-development 2026-05-15T05:58:21+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-recalls-doxorubicin-liposome-injection-due-to-glass-particle-contamination 2026-05-15T05:57:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-recalls-doxorubicin-liposome-injection-due-to-glass-particle-contamination 2026-05-15T05:57:24+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-topaz-trial-finds-bone-density-drugs-do-not-prevent-fractures-in-brittle-bone-disease 2026-05-15T05:56:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-topaz-trial-finds-bone-density-drugs-do-not-prevent-fractures-in-brittle-bone-disease 2026-05-15T05:56:58+00:00 hourly 0.9 https://trial.medpath.com/news/breast-cancer-drug-shows-promise-for-treatment-resistant-uterine-cancer-in-phase-ii-trial 2026-05-15T05:55:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breast-cancer-drug-shows-promise-for-treatment-resistant-uterine-cancer-in-phase-ii-trial 2026-05-15T05:55:19+00:00 hourly 0.9 https://trial.medpath.com/news/datar-cancer-genetics-receives-us-fda-clearance-for-celldx-tissue-comprehensive-genomic-profiling-assay 2026-05-15T05:48:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/datar-cancer-genetics-receives-us-fda-clearance-for-celldx-tissue-comprehensive-genomic-profiling-assay 2026-05-15T05:48:24+00:00 hourly 0.9 https://trial.medpath.com/news/nuwellis-advances-pediatric-expansion-of-aquadex-system-following-fda-pre-submission-meeting 2026-05-15T05:44:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuwellis-advances-pediatric-expansion-of-aquadex-system-following-fda-pre-submission-meeting 2026-05-15T05:44:51+00:00 hourly 0.9 https://trial.medpath.com/news/inmune-bio-receives-fda-fast-track-designation-for-xpro1595-in-early-alzheimer-s-disease 2026-05-15T05:41:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inmune-bio-receives-fda-fast-track-designation-for-xpro1595-in-early-alzheimer-s-disease 2026-05-15T05:41:01+00:00 hourly 0.9 https://trial.medpath.com/news/sonomotion-s-break-wave-lithotripsy-device-meets-pivotal-trial-endpoints-receives-fda-clearance 2026-05-15T05:40:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sonomotion-s-break-wave-lithotripsy-device-meets-pivotal-trial-endpoints-receives-fda-clearance 2026-05-15T05:40:04+00:00 hourly 0.9 https://trial.medpath.com/news/mezzion-secures-strategic-financing-to-advance-phase-3-trial-of-udenafil-for-fontan-circulation 2026-05-15T05:39:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mezzion-secures-strategic-financing-to-advance-phase-3-trial-of-udenafil-for-fontan-circulation 2026-05-15T05:39:18+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-files-for-japanese-approval-of-sparsentan-for-iga-nephropathy-citing-significant-proteinuria-reduction 2026-05-15T05:37:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chugai-files-for-japanese-approval-of-sparsentan-for-iga-nephropathy-citing-significant-proteinuria-reduction 2026-05-15T05:37:18+00:00 hourly 0.9 https://trial.medpath.com/news/nevian-life-science-achieves-historic-milestone-with-first-bangladeshi-pharmaceutical-exports-to-canada 2026-05-15T05:36:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nevian-life-science-achieves-historic-milestone-with-first-bangladeshi-pharmaceutical-exports-to-canada 2026-05-15T05:36:47+00:00 hourly 0.9 https://trial.medpath.com/news/create-medicines-raises-122-million-to-advance-in-vivo-car-t-therapies-for-cancer-and-autoimmune-diseases 2026-05-15T05:35:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/create-medicines-raises-122-million-to-advance-in-vivo-car-t-therapies-for-cancer-and-autoimmune-diseases 2026-05-15T05:35:19+00:00 hourly 0.9 https://trial.medpath.com/news/galmed-develops-brain-penetrating-odf-formulation-of-scd1-inhibitor-aramchol-for-parkinson-s-disease 2026-05-15T05:31:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galmed-develops-brain-penetrating-odf-formulation-of-scd1-inhibitor-aramchol-for-parkinson-s-disease 2026-05-15T05:31:41+00:00 hourly 0.9 https://trial.medpath.com/news/uc-davis-tests-novel-immunotherapy-chemotherapy-sequence-for-high-risk-diffuse-large-b-cell-lymphoma 2026-05-15T05:30:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-davis-tests-novel-immunotherapy-chemotherapy-sequence-for-high-risk-diffuse-large-b-cell-lymphoma 2026-05-15T05:30:26+00:00 hourly 0.9 https://trial.medpath.com/news/ema-wellness-and-mira-analytics-form-exclusive-partnership-to-deploy-ai-driven-endpoint-validation-in-cns-clinical-trials 2026-05-15T05:30:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-wellness-and-mira-analytics-form-exclusive-partnership-to-deploy-ai-driven-endpoint-validation-in-cns-clinical-trials 2026-05-15T05:30:01+00:00 hourly 0.9 https://trial.medpath.com/news/eyepoint-s-duravyu-eye-drug-clears-safety-review-late-stage-trials-to-continue 2026-05-15T05:29:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eyepoint-s-duravyu-eye-drug-clears-safety-review-late-stage-trials-to-continue 2026-05-15T05:29:50+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-s-tau-targeting-alzheimer-s-drug-shows-promise-despite-missing-primary-endpoint-in-phase-2-study 2026-05-15T05:26:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-s-tau-targeting-alzheimer-s-drug-shows-promise-despite-missing-primary-endpoint-in-phase-2-study 2026-05-15T05:26:06+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-drug-l1-79-shows-promising-results-for-core-autism-symptoms-in-adolescent-trial 2026-05-15T05:25:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-drug-l1-79-shows-promising-results-for-core-autism-symptoms-in-adolescent-trial 2026-05-15T05:25:33+00:00 hourly 0.9 https://trial.medpath.com/news/cuhk-completes-first-clinical-trial-of-glp-1-diabetes-drug-for-severe-stroke-recovery 2026-05-15T05:24:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cuhk-completes-first-clinical-trial-of-glp-1-diabetes-drug-for-severe-stroke-recovery 2026-05-15T05:24:53+00:00 hourly 0.9 https://trial.medpath.com/news/medipost-s-cartistem-achieves-all-primary-endpoints-in-japan-phase-3-trial-for-knee-osteoarthritis 2026-05-15T05:23:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medipost-s-cartistem-achieves-all-primary-endpoints-in-japan-phase-3-trial-for-knee-osteoarthritis 2026-05-15T05:23:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-tessie-tasipimidine-for-canine-noise-aversion-and-separation-anxiety 2026-05-15T05:17:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-tessie-tasipimidine-for-canine-noise-aversion-and-separation-anxiety 2026-05-15T05:17:55+00:00 hourly 0.9 https://trial.medpath.com/news/ipsen-unveils-corabotase-first-in-class-recombinant-neuroinhibitor-for-aesthetic-applications 2026-05-15T05:14:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ipsen-unveils-corabotase-first-in-class-recombinant-neuroinhibitor-for-aesthetic-applications 2026-05-15T05:14:41+00:00 hourly 0.9 https://trial.medpath.com/news/bain-backed-tanabe-pharma-targets-three-new-drug-launches-annually-in-japan-led-by-rare-disease-candidate 2026-05-15T05:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bain-backed-tanabe-pharma-targets-three-new-drug-launches-annually-in-japan-led-by-rare-disease-candidate 2026-05-15T05:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/gccl-and-gempharmatech-forge-strategic-alliance-to-bridge-non-clinical-and-clinical-drug-development 2026-05-15T05:08:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gccl-and-gempharmatech-forge-strategic-alliance-to-bridge-non-clinical-and-clinical-drug-development 2026-05-15T05:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/spark-biomedical-appoints-anja-krammer-as-ceo-to-drive-bioelectronic-medicine-platform-forward 2026-05-15T05:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spark-biomedical-appoints-anja-krammer-as-ceo-to-drive-bioelectronic-medicine-platform-forward 2026-05-15T05:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-gene-therapy-khn921-for-hypertrophic-cardiomyopathy-phase-i-ii-trial 2026-05-15T04:57:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-gene-therapy-khn921-for-hypertrophic-cardiomyopathy-phase-i-ii-trial 2026-05-15T04:57:44+00:00 hourly 0.9 https://trial.medpath.com/news/major-anti-aging-drug-development-setbacks-reveal-new-opportunities-for-precision-medicine-approaches 2026-05-15T04:56:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-anti-aging-drug-development-setbacks-reveal-new-opportunities-for-precision-medicine-approaches 2026-05-15T04:56:36+00:00 hourly 0.9 https://trial.medpath.com/news/nyxoah-s-genio-system-drives-22-sequential-u-s-revenue-growth-in-q2-2026-secures-110-million-financing 2026-05-15T04:50:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nyxoah-s-genio-system-drives-22-sequential-u-s-revenue-growth-in-q2-2026-secures-110-million-financing 2026-05-15T04:50:53+00:00 hourly 0.9 https://trial.medpath.com/news/curium-knocks-out-novartis-cancer-drug-patents-in-generics-fight 2026-05-15T04:49:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curium-knocks-out-novartis-cancer-drug-patents-in-generics-fight 2026-05-15T04:49:39+00:00 hourly 0.9 https://trial.medpath.com/news/qureight-partners-with-mediar-therapeutics-to-deploy-ai-powered-imaging-analytics-in-phase-2-systemic-sclerosis-trial 2026-05-15T04:48:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qureight-partners-with-mediar-therapeutics-to-deploy-ai-powered-imaging-analytics-in-phase-2-systemic-sclerosis-trial 2026-05-15T04:48:54+00:00 hourly 0.9 https://trial.medpath.com/news/merit-and-mti-form-strategic-partnership-to-revolutionize-spirometry-data-collection-in-clinical-trials 2026-05-15T04:48:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merit-and-mti-form-strategic-partnership-to-revolutionize-spirometry-data-collection-in-clinical-trials 2026-05-15T04:48:33+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-affirms-noninfringement-ruling-in-actelion-mylan-hypertension-drug-patent-dispute 2026-05-15T04:48:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-affirms-noninfringement-ruling-in-actelion-mylan-hypertension-drug-patent-dispute 2026-05-15T04:48:16+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-khn921-gene-therapy-trial-for-mybpc3-associated-hypertrophic-cardiomyopathy 2026-05-15T04:47:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-khn921-gene-therapy-trial-for-mybpc3-associated-hypertrophic-cardiomyopathy 2026-05-15T04:47:05+00:00 hourly 0.9 https://trial.medpath.com/news/catalent-partners-with-elpida-therapeutics-to-advance-aav-gene-therapy-for-ultra-rare-spg50-disease 2026-05-15T04:43:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/catalent-partners-with-elpida-therapeutics-to-advance-aav-gene-therapy-for-ultra-rare-spg50-disease 2026-05-15T04:43:08+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-unveils-next-generation-obesity-pipeline-at-ada-2026-featuring-oral-daily-and-weekly-glp-1-candidates-amylin-analog-and-inhbe-sirna 2026-05-15T04:33:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovent-unveils-next-generation-obesity-pipeline-at-ada-2026-featuring-oral-daily-and-weekly-glp-1-candidates-amylin-analog-and-inhbe-sirna 2026-05-15T04:33:20+00:00 hourly 0.9 https://trial.medpath.com/news/andera-partners-leads-20-million-series-d-for-rivermark-medical-s-bph-device-therapy 2026-05-15T04:29:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/andera-partners-leads-20-million-series-d-for-rivermark-medical-s-bph-device-therapy 2026-05-15T04:29:32+00:00 hourly 0.9 https://trial.medpath.com/news/mhra-strengthens-safety-warnings-for-finasteride-and-dutasteride-over-psychiatric-and-sexual-side-effects 2026-05-15T04:26:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mhra-strengthens-safety-warnings-for-finasteride-and-dutasteride-over-psychiatric-and-sexual-side-effects 2026-05-15T04:26:15+00:00 hourly 0.9 https://trial.medpath.com/news/nexentis-subsidiary-mitocarex-achieves-drug-discovery-milestone-with-mitoline-r-platform-for-cancer-and-inflammatory-disease-treatment 2026-05-15T04:16:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nexentis-subsidiary-mitocarex-achieves-drug-discovery-milestone-with-mitoline-r-platform-for-cancer-and-inflammatory-disease-treatment 2026-05-15T04:16:22+00:00 hourly 0.9 https://trial.medpath.com/news/nvision-raises-55m-to-advance-quantum-enhanced-cancer-imaging-and-drug-development-platform 2026-05-15T04:05:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nvision-raises-55m-to-advance-quantum-enhanced-cancer-imaging-and-drug-development-platform 2026-05-15T04:05:31+00:00 hourly 0.9 https://trial.medpath.com/news/zenas-biopharma-initiates-phase-1-trial-of-zb021-first-oral-il-17-inhibitor-for-autoimmune-diseases 2026-05-15T04:05:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zenas-biopharma-initiates-phase-1-trial-of-zb021-first-oral-il-17-inhibitor-for-autoimmune-diseases 2026-05-15T04:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/veristat-launches-ai-powered-biostatistics-platform-to-accelerate-clinical-trial-data-analysis 2026-05-15T04:01:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veristat-launches-ai-powered-biostatistics-platform-to-accelerate-clinical-trial-data-analysis 2026-05-15T04:01:19+00:00 hourly 0.9 https://trial.medpath.com/news/uae-becomes-first-country-to-approve-astrazeneca-s-baxfendy-for-resistant-hypertension 2026-05-15T04:00:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uae-becomes-first-country-to-approve-astrazeneca-s-baxfendy-for-resistant-hypertension 2026-05-15T04:00:18+00:00 hourly 0.9 https://trial.medpath.com/news/andzonbio2-partners-with-cambridge-to-develop-first-in-class-neuroinflammation-therapeutics 2026-05-15T03:58:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/andzonbio2-partners-with-cambridge-to-develop-first-in-class-neuroinflammation-therapeutics 2026-05-15T03:58:06+00:00 hourly 0.9 https://trial.medpath.com/news/onco-innovations-partners-with-astrazeneca-and-gsk-on-ai-driven-oncology-research-collaborations 2026-05-15T03:54:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onco-innovations-partners-with-astrazeneca-and-gsk-on-ai-driven-oncology-research-collaborations 2026-05-15T03:54:39+00:00 hourly 0.9 https://trial.medpath.com/news/ektah-s-novel-obesity-drug-shows-promise-in-reducing-weight-rebound-after-glp-1-treatment-discontinuation 2026-05-15T03:45:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ektah-s-novel-obesity-drug-shows-promise-in-reducing-weight-rebound-after-glp-1-treatment-discontinuation 2026-05-15T03:45:54+00:00 hourly 0.9 https://trial.medpath.com/news/neurocatch-partners-with-geneva-foundation-to-advance-military-cognitive-health-research 2026-05-15T03:38:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurocatch-partners-with-geneva-foundation-to-advance-military-cognitive-health-research 2026-05-15T03:38:58+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-challenges-traditional-view-of-thyroid-eye-disease-progression 2026-05-15T03:38:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-challenges-traditional-view-of-thyroid-eye-disease-progression 2026-05-15T03:38:33+00:00 hourly 0.9 https://trial.medpath.com/news/vicentra-scales-kaleido-insulin-patch-pump-production-triples-manufacturing-capacity 2026-05-15T03:33:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vicentra-scales-kaleido-insulin-patch-pump-production-triples-manufacturing-capacity 2026-05-15T03:33:33+00:00 hourly 0.9 https://trial.medpath.com/news/aquestive-therapeutics-secures-150-million-debt-refinancing-to-support-anaphylm-launch-preparations 2026-05-15T03:30:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aquestive-therapeutics-secures-150-million-debt-refinancing-to-support-anaphylm-launch-preparations 2026-05-15T03:30:13+00:00 hourly 0.9 https://trial.medpath.com/news/novel-anti-hiv-car-t-cell-therapy-shows-promise-for-durable-viral-control-in-early-clinical-trial 2026-05-15T03:27:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-anti-hiv-car-t-cell-therapy-shows-promise-for-durable-viral-control-in-early-clinical-trial 2026-05-15T03:27:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-rare-disease-evidence-principles-eligibility-to-repair-biotechnologies-mrna-therapy-for-homozygous-familial-hypercholesterolemia 2026-05-15T03:16:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-rare-disease-evidence-principles-eligibility-to-repair-biotechnologies-mrna-therapy-for-homozygous-familial-hypercholesterolemia 2026-05-15T03:16:45+00:00 hourly 0.9 https://trial.medpath.com/news/dare-bioscience-reports-positive-interim-phase-3-results-for-ovaprene-hormone-free-contraceptive 2026-05-15T03:10:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dare-bioscience-reports-positive-interim-phase-3-results-for-ovaprene-hormone-free-contraceptive 2026-05-15T03:10:28+00:00 hourly 0.9 https://trial.medpath.com/news/halia-therapeutics-reports-67-hematological-improvement-rate-with-ofirnoflast-in-lower-risk-mds-phase-2-trial 2026-05-15T03:06:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/halia-therapeutics-reports-67-hematological-improvement-rate-with-ofirnoflast-in-lower-risk-mds-phase-2-trial 2026-05-15T03:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-emiltatug-ledadotin-for-adenoid-cystic-carcinoma 2026-05-15T03:02:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-emiltatug-ledadotin-for-adenoid-cystic-carcinoma 2026-05-15T03:02:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-first-ever-clearance-for-continuous-ai-sepsis-monitoring-system 2026-05-15T03:01:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-first-ever-clearance-for-continuous-ai-sepsis-monitoring-system 2026-05-15T03:01:41+00:00 hourly 0.9 https://trial.medpath.com/news/enterome-s-eo2463-shows-promising-cd8-t-cell-expansion-in-phase-2-indolent-non-hodgkin-lymphoma-trial 2026-05-15T02:59:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enterome-s-eo2463-shows-promising-cd8-t-cell-expansion-in-phase-2-indolent-non-hodgkin-lymphoma-trial 2026-05-15T02:59:44+00:00 hourly 0.9 https://trial.medpath.com/news/enterprise-therapeutics-etd001-demonstrates-significant-lung-function-improvement-in-phase-2-cystic-fibrosis-trial 2026-05-15T02:59:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enterprise-therapeutics-etd001-demonstrates-significant-lung-function-improvement-in-phase-2-cystic-fibrosis-trial 2026-05-15T02:59:08+00:00 hourly 0.9 https://trial.medpath.com/news/infex-therapeutics-secures-ps4-3m-to-advance-anti-virulence-therapy-resp-x-following-phase-2a-trial-completion 2026-05-15T02:54:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/infex-therapeutics-secures-ps4-3m-to-advance-anti-virulence-therapy-resp-x-following-phase-2a-trial-completion 2026-05-15T02:54:35+00:00 hourly 0.9 https://trial.medpath.com/news/astronautx-appoints-dr-michelle-mellion-as-cmo-to-lead-novel-sleep-based-alzheimer-s-therapeutics-into-clinical-development 2026-05-15T02:50:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astronautx-appoints-dr-michelle-mellion-as-cmo-to-lead-novel-sleep-based-alzheimer-s-therapeutics-into-clinical-development 2026-05-15T02:50:13+00:00 hourly 0.9 https://trial.medpath.com/news/justice-department-charges-455-in-6-5-billion-healthcare-fraud-sweep-spotlighting-cardiovascular-screening-scheme 2026-05-14T22:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/justice-department-charges-455-in-6-5-billion-healthcare-fraud-sweep-spotlighting-cardiovascular-screening-scheme 2026-05-14T22:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/cardinal-health-demonstrates-strong-financial-momentum-amid-evolving-pharmaceutical-distribution-landscape 2026-05-14T20:55:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cardinal-health-demonstrates-strong-financial-momentum-amid-evolving-pharmaceutical-distribution-landscape 2026-05-14T20:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/focal-therapy-for-localized-prostate-cancer-promise-progress-and-unanswered-questions 2026-05-14T14:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/focal-therapy-for-localized-prostate-cancer-promise-progress-and-unanswered-questions 2026-05-14T14:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/prescriptions-for-unproven-cancer-treatment-surge-250-after-mel-gibson-s-endorsement-on-joe-rogan-podcast 2026-05-13T14:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prescriptions-for-unproven-cancer-treatment-surge-250-after-mel-gibson-s-endorsement-on-joe-rogan-podcast 2026-05-13T14:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/kailera-and-hengrui-present-promising-ribupatide-data-at-ada-2026-demonstrating-strong-weight-loss-efficacy 2026-05-13T11:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kailera-and-hengrui-present-promising-ribupatide-data-at-ada-2026-demonstrating-strong-weight-loss-efficacy 2026-05-13T11:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/mira-pharmaceuticals-skny-1-shows-promising-oral-bioavailability-and-brain-penetration-in-preclinical-obesity-and-addiction-studies 2026-05-13T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mira-pharmaceuticals-skny-1-shows-promising-oral-bioavailability-and-brain-penetration-in-preclinical-obesity-and-addiction-studies 2026-05-13T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-cas-systems-emerge-as-programmable-weapons-against-mrsa-biofilms 2026-05-12T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-cas-systems-emerge-as-programmable-weapons-against-mrsa-biofilms 2026-05-12T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/alignment-healthcare-doubles-net-income-as-medicare-advantage-medical-costs-ease 2026-05-12T22:34:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alignment-healthcare-doubles-net-income-as-medicare-advantage-medical-costs-ease 2026-05-12T22:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/syndax-presents-comprehensive-revuforj-data-at-major-oncology-conferences-highlighting-post-transplant-efficacy 2026-05-12T14:54:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/syndax-presents-comprehensive-revuforj-data-at-major-oncology-conferences-highlighting-post-transplant-efficacy 2026-05-12T14:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-cancer-vaccine-market-to-surpass-1-20-billion-in-2026-as-personalized-oncology-gains-momentum 2026-05-12T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrna-cancer-vaccine-market-to-surpass-1-20-billion-in-2026-as-personalized-oncology-gains-momentum 2026-05-12T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/ceribell-reports-29-revenue-growth-in-q1-2026-launches-neonate-and-pediatric-eeg-products 2026-05-12T09:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ceribell-reports-29-revenue-growth-in-q1-2026-launches-neonate-and-pediatric-eeg-products 2026-05-12T09:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/hydrocortisone-linked-to-65-lower-mortality-in-severe-cap-while-other-corticosteroids-show-no-benefit 2026-05-12T07:56:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hydrocortisone-linked-to-65-lower-mortality-in-severe-cap-while-other-corticosteroids-show-no-benefit 2026-05-12T07:56:32+00:00 hourly 0.9 https://trial.medpath.com/news/delos-capital-and-ap-biosciences-launch-strategic-partnership-to-accelerate-next-generation-antibody-development 2026-05-12T07:54:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delos-capital-and-ap-biosciences-launch-strategic-partnership-to-accelerate-next-generation-antibody-development 2026-05-12T07:54:56+00:00 hourly 0.9 https://trial.medpath.com/news/macrogenics-sells-gmp-manufacturing-operations-to-bora-pharmaceuticals-for-122-5-million 2026-05-12T07:52:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/macrogenics-sells-gmp-manufacturing-operations-to-bora-pharmaceuticals-for-122-5-million 2026-05-12T07:52:02+00:00 hourly 0.9 https://trial.medpath.com/news/aldevron-and-minaris-renew-strategic-partnership-to-accelerate-gene-modified-cell-therapy-development 2026-05-12T07:47:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aldevron-and-minaris-renew-strategic-partnership-to-accelerate-gene-modified-cell-therapy-development 2026-05-12T07:47:46+00:00 hourly 0.9 https://trial.medpath.com/news/mrna-flu-vaccine-shows-27-efficacy-improvement-in-major-clinical-trial 2026-05-12T07:40:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrna-flu-vaccine-shows-27-efficacy-improvement-in-major-clinical-trial 2026-05-12T07:40:46+00:00 hourly 0.9 https://trial.medpath.com/news/obinutuzumab-b-cell-depletion-significantly-reduces-corticosteroid-requiring-chronic-gvhd-in-phase-ii-trial 2026-05-12T07:38:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/obinutuzumab-b-cell-depletion-significantly-reduces-corticosteroid-requiring-chronic-gvhd-in-phase-ii-trial 2026-05-12T07:38:48+00:00 hourly 0.9 https://trial.medpath.com/news/anaveon-presents-positive-anv600-clinical-data-at-asco-2026-seeks-partners-for-oncology-portfolio 2026-05-12T07:36:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anaveon-presents-positive-anv600-clinical-data-at-asco-2026-seeks-partners-for-oncology-portfolio 2026-05-12T07:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/transpire-bio-achieves-fda-filing-acceptance-for-generic-high-strength-trelegy-ellipta-with-potential-180-day-market-exclusivity 2026-05-12T07:35:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transpire-bio-achieves-fda-filing-acceptance-for-generic-high-strength-trelegy-ellipta-with-potential-180-day-market-exclusivity 2026-05-12T07:35:38+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-to-acquire-nuvalent-for-10-6-billion-in-major-lung-cancer-pipeline-expansion 2026-05-12T07:32:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-to-acquire-nuvalent-for-10-6-billion-in-major-lung-cancer-pipeline-expansion 2026-05-12T07:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/cellular-intelligence-acquires-novo-nordisk-s-parkinson-s-cell-therapy-program-with-fda-fast-track-status 2026-05-12T07:24:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellular-intelligence-acquires-novo-nordisk-s-parkinson-s-cell-therapy-program-with-fda-fast-track-status 2026-05-12T07:24:45+00:00 hourly 0.9 https://trial.medpath.com/news/myrtelle-reports-encouraging-clinical-data-for-myr-101-gene-therapy-in-canavan-disease-at-asgct-2026 2026-05-12T07:23:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/myrtelle-reports-encouraging-clinical-data-for-myr-101-gene-therapy-in-canavan-disease-at-asgct-2026 2026-05-12T07:23:15+00:00 hourly 0.9 https://trial.medpath.com/news/om1-s-ai-platform-enables-landmark-650000-patient-real-world-evidence-study-supporting-fda-approval-of-hologic-s-hpv-screening-assay 2026-05-12T07:19:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/om1-s-ai-platform-enables-landmark-650000-patient-real-world-evidence-study-supporting-fda-approval-of-hologic-s-hpv-screening-assay 2026-05-12T07:19:38+00:00 hourly 0.9 https://trial.medpath.com/news/harvard-university-expands-research-alliance-with-northpond-labs-to-accelerate-healthcare-innovation-translation 2026-05-12T07:19:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harvard-university-expands-research-alliance-with-northpond-labs-to-accelerate-healthcare-innovation-translation 2026-05-12T07:19:05+00:00 hourly 0.9 https://trial.medpath.com/news/form-bio-launches-ai-powered-formmanufacturing-platform-to-address-cgt-manufacturing-bottlenecks 2026-05-12T07:18:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/form-bio-launches-ai-powered-formmanufacturing-platform-to-address-cgt-manufacturing-bottlenecks 2026-05-12T07:18:25+00:00 hourly 0.9 https://trial.medpath.com/news/heron-therapeutics-reports-mixed-q1-2026-results-with-strong-acute-care-growth-despite-overall-revenue-decline 2026-05-12T07:13:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heron-therapeutics-reports-mixed-q1-2026-results-with-strong-acute-care-growth-despite-overall-revenue-decline 2026-05-12T07:13:44+00:00 hourly 0.9 https://trial.medpath.com/news/invivyd-s-covid-monoclonal-antibody-shows-superior-tolerability-profile-compared-to-mrna-and-protein-vaccines 2026-05-12T07:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/invivyd-s-covid-monoclonal-antibody-shows-superior-tolerability-profile-compared-to-mrna-and-protein-vaccines 2026-05-12T07:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/curacle-and-maptics-license-bispecific-antibody-mt-103-to-memento-medicines-in-1-08-billion-deal-for-retinal-disease-treatment 2026-05-12T07:10:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curacle-and-maptics-license-bispecific-antibody-mt-103-to-memento-medicines-in-1-08-billion-deal-for-retinal-disease-treatment 2026-05-12T07:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/fusion-antibodies-advances-dr5-humanised-antibody-for-treatment-resistant-cancers-with-extended-grant-support 2026-05-12T07:09:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fusion-antibodies-advances-dr5-humanised-antibody-for-treatment-resistant-cancers-with-extended-grant-support 2026-05-12T07:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/reponex-pharmaceuticals-secures-european-patent-for-inflammatory-bowel-disease-treatment-targeting-4-7-billion-market 2026-05-12T07:09:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reponex-pharmaceuticals-secures-european-patent-for-inflammatory-bowel-disease-treatment-targeting-4-7-billion-market 2026-05-12T07:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/bologna-s-cellply-raises-eur7-15-million-to-advance-single-cell-analysis-platform-for-cell-therapy-development 2026-05-12T07:08:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bologna-s-cellply-raises-eur7-15-million-to-advance-single-cell-analysis-platform-for-cell-therapy-development 2026-05-12T07:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/basf-launches-new-fermentation-plant-for-biological-crop-protection-products-in-germany 2026-05-12T07:05:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/basf-launches-new-fermentation-plant-for-biological-crop-protection-products-in-germany 2026-05-12T07:05:36+00:00 hourly 0.9 https://trial.medpath.com/news/alvotech-completes-fda-surveillance-inspection-remains-on-track-for-bla-resubmissions 2026-05-12T07:05:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alvotech-completes-fda-surveillance-inspection-remains-on-track-for-bla-resubmissions 2026-05-12T07:05:18+00:00 hourly 0.9 https://trial.medpath.com/news/first-randomized-trial-of-rna-therapy-in-heart-failure-shows-promise-for-novel-treatment-approach 2026-05-12T07:00:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-randomized-trial-of-rna-therapy-in-heart-failure-shows-promise-for-novel-treatment-approach 2026-05-12T07:00:21+00:00 hourly 0.9 https://trial.medpath.com/news/pentixapharm-submits-ind-to-fda-for-phase-3-panda-trial-of-first-in-class-cxcr4-targeted-cardiovascular-diagnostic 2026-05-12T06:56:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pentixapharm-submits-ind-to-fda-for-phase-3-panda-trial-of-first-in-class-cxcr4-targeted-cardiovascular-diagnostic 2026-05-12T06:56:09+00:00 hourly 0.9 https://trial.medpath.com/news/daiichi-sankyo-unveils-ambitious-five-year-plan-to-become-global-top-five-oncology-company-by-2035 2026-05-12T06:53:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daiichi-sankyo-unveils-ambitious-five-year-plan-to-become-global-top-five-oncology-company-by-2035 2026-05-12T06:53:59+00:00 hourly 0.9 https://trial.medpath.com/news/emvision-expands-pivotal-fda-trial-to-include-acute-ischaemia-detection-for-stroke-diagnosis-device 2026-05-12T06:51:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emvision-expands-pivotal-fda-trial-to-include-acute-ischaemia-detection-for-stroke-diagnosis-device 2026-05-12T06:51:27+00:00 hourly 0.9 https://trial.medpath.com/news/robotic-wheelchair-market-to-reach-usd-425-72-million-by-2035-driven-by-ai-navigation-and-brain-computer-interfaces 2026-05-12T06:47:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/robotic-wheelchair-market-to-reach-usd-425-72-million-by-2035-driven-by-ai-navigation-and-brain-computer-interfaces 2026-05-12T06:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/low-dose-digoxin-fails-to-meet-primary-endpoint-in-largest-heart-failure-trial-despite-hospitalization-benefits 2026-05-12T06:42:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/low-dose-digoxin-fails-to-meet-primary-endpoint-in-largest-heart-failure-trial-despite-hospitalization-benefits 2026-05-12T06:42:26+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-rna-therapy-cdr132l-fails-to-meet-primary-endpoint-in-heart-failure-trial 2026-05-12T06:42:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-s-rna-therapy-cdr132l-fails-to-meet-primary-endpoint-in-heart-failure-trial 2026-05-12T06:42:15+00:00 hourly 0.9 https://trial.medpath.com/news/rwanda-s-sovereign-bet-on-science-akagera-medicines-advances-novel-tb-drug-akg-100-into-phase-i-trials 2026-05-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rwanda-s-sovereign-bet-on-science-akagera-medicines-advances-novel-tb-drug-akg-100-into-phase-i-trials 2026-05-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/unc-health-pursues-certificate-of-need-approval-for-new-hospitals-in-asheville-and-wilmington 2026-05-11T15:58:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unc-health-pursues-certificate-of-need-approval-for-new-hospitals-in-asheville-and-wilmington 2026-05-11T15:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/belapectin-shows-promise-in-preventing-esophageal-varices-in-mash-cirrhosis-patients 2026-05-11T12:13:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belapectin-shows-promise-in-preventing-esophageal-varices-in-mash-cirrhosis-patients 2026-05-11T12:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/bridge-to-life-s-vitasmart-hope-technology-shows-promise-for-expanding-liver-transplant-donor-pool 2026-05-11T12:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bridge-to-life-s-vitasmart-hope-technology-shows-promise-for-expanding-liver-transplant-donor-pool 2026-05-11T12:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/us-pharmaceutical-excipients-market-to-reach-5-58-billion-by-2035-driven-by-biologics-and-advanced-formulations 2026-05-11T06:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-pharmaceutical-excipients-market-to-reach-5-58-billion-by-2035-driven-by-biologics-and-advanced-formulations 2026-05-11T06:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/aldeyra-therapeutics-faces-securities-class-action-over-alleged-misrepresentation-of-reproxalap-trial-data-following-fda-rejection 2026-05-11T04:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aldeyra-therapeutics-faces-securities-class-action-over-alleged-misrepresentation-of-reproxalap-trial-data-following-fda-rejection 2026-05-11T04:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-secures-procedural-victory-in-mrna-patent-dispute-against-pfizer-biontech-covid-19-vaccine 2026-05-10T08:40:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-secures-procedural-victory-in-mrna-patent-dispute-against-pfizer-biontech-covid-19-vaccine 2026-05-10T08:40:21+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-drug-regulator-mandates-safety-reporting-from-market-launch-date-to-strengthen-patient-monitoring 2026-05-10T08:37:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-s-drug-regulator-mandates-safety-reporting-from-market-launch-date-to-strengthen-patient-monitoring 2026-05-10T08:37:11+00:00 hourly 0.9 https://trial.medpath.com/news/roche-launches-india-s-first-subcutaneous-immunotherapy-for-lung-cancer-reducing-treatment-time-to-seven-minutes 2026-05-10T08:07:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-launches-india-s-first-subcutaneous-immunotherapy-for-lung-cancer-reducing-treatment-time-to-seven-minutes 2026-05-10T08:07:28+00:00 hourly 0.9 https://trial.medpath.com/news/ensoma-reports-first-clinical-safety-data-for-groundbreaking-in-vivo-hematopoietic-stem-cell-gene-therapy 2026-05-10T08:02:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ensoma-reports-first-clinical-safety-data-for-groundbreaking-in-vivo-hematopoietic-stem-cell-gene-therapy 2026-05-10T08:02:19+00:00 hourly 0.9 https://trial.medpath.com/news/onco-innovations-advances-pnkp-inhibitor-toward-clinical-trials-with-nucro-technics-bioanalytical-partnership 2026-05-10T08:01:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onco-innovations-advances-pnkp-inhibitor-toward-clinical-trials-with-nucro-technics-bioanalytical-partnership 2026-05-10T08:01:38+00:00 hourly 0.9 https://trial.medpath.com/news/ema-recommends-first-veterinary-vaccine-using-self-amplifying-rna-technology-for-cat-protection 2026-05-10T07:58:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-recommends-first-veterinary-vaccine-using-self-amplifying-rna-technology-for-cat-protection 2026-05-10T07:58:31+00:00 hourly 0.9 https://trial.medpath.com/news/inhibrx-s-inbrx-106-shows-44-response-rate-in-head-and-neck-cancer-trial-doubling-pembrolizumab-efficacy 2026-05-10T07:47:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inhibrx-s-inbrx-106-shows-44-response-rate-in-head-and-neck-cancer-trial-doubling-pembrolizumab-efficacy 2026-05-10T07:47:43+00:00 hourly 0.9 https://trial.medpath.com/news/fudan-cup-002-trial-demonstrates-strong-efficacy-of-anti-pd-1-triple-combination-in-second-line-cancer-of-unknown-primary-treatment 2026-05-10T07:47:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fudan-cup-002-trial-demonstrates-strong-efficacy-of-anti-pd-1-triple-combination-in-second-line-cancer-of-unknown-primary-treatment 2026-05-10T07:47:33+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-bet-inhibitor-nhwd-870-receives-breakthrough-therapy-designation-for-rare-nut-carcinoma 2026-05-10T07:46:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-bet-inhibitor-nhwd-870-receives-breakthrough-therapy-designation-for-rare-nut-carcinoma 2026-05-10T07:46:40+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-dual-purpose-medication-for-canine-separation-anxiety-and-noise-aversion 2026-05-10T07:45:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-dual-purpose-medication-for-canine-separation-anxiety-and-noise-aversion 2026-05-10T07:45:41+00:00 hourly 0.9 https://trial.medpath.com/news/francis-medical-receives-fda-clearance-for-vanquish-water-vapor-ablation-system-for-localized-prostate-cancer 2026-05-10T07:41:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/francis-medical-receives-fda-clearance-for-vanquish-water-vapor-ablation-system-for-localized-prostate-cancer 2026-05-10T07:41:10+00:00 hourly 0.9 https://trial.medpath.com/news/hovione-and-idc-launch-commercial-intranasal-drug-delivery-platform-with-single-use-dry-powder-device 2026-05-10T07:34:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hovione-and-idc-launch-commercial-intranasal-drug-delivery-platform-with-single-use-dry-powder-device 2026-05-10T07:34:19+00:00 hourly 0.9 https://trial.medpath.com/news/analysts-maintain-strong-buy-consensus-on-cullinan-management-cgem-with-significant-upside-potential 2026-05-09T12:55:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/analysts-maintain-strong-buy-consensus-on-cullinan-management-cgem-with-significant-upside-potential 2026-05-09T12:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/hongene-biotech-demonstrates-advanced-sirna-manufacturing-capabilities-through-siranbio-s-dual-target-hepatitis-b-program 2026-05-09T10:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hongene-biotech-demonstrates-advanced-sirna-manufacturing-capabilities-through-siranbio-s-dual-target-hepatitis-b-program 2026-05-09T10:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/brain-aging-study-reveals-coordinated-cellular-remodeling-in-the-hippocampus-between-ages-50-and-75 2026-05-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-aging-study-reveals-coordinated-cellular-remodeling-in-the-hippocampus-between-ages-50-and-75 2026-05-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/actio-biosciences-initiates-phase-1b-2-trial-of-abs-1230-for-rare-pediatric-epilepsy 2026-05-08T17:54:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actio-biosciences-initiates-phase-1b-2-trial-of-abs-1230-for-rare-pediatric-epilepsy 2026-05-08T17:54:59+00:00 hourly 0.9 https://trial.medpath.com/news/vitamin-b12-s-role-in-mitochondrial-health-and-muscle-function-new-insights-into-healthy-aging 2026-05-08T17:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vitamin-b12-s-role-in-mitochondrial-health-and-muscle-function-new-insights-into-healthy-aging 2026-05-08T17:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/gabather-initiates-phase-ii-totems-trial-for-gt-002-in-schizophrenia-spectrum-disorders 2026-05-08T17:40:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gabather-initiates-phase-ii-totems-trial-for-gt-002-in-schizophrenia-spectrum-disorders 2026-05-08T17:40:30+00:00 hourly 0.9 https://trial.medpath.com/news/modicus-prime-secures-8m-to-scale-ai-compliance-platform-for-pharmaceutical-industry 2026-05-08T10:04:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/modicus-prime-secures-8m-to-scale-ai-compliance-platform-for-pharmaceutical-industry 2026-05-08T10:04:22+00:00 hourly 0.9 https://trial.medpath.com/news/yarmouk-university-secures-u-s-patent-for-solvent-free-dry-coating-technology-in-pharmaceutical-manufacturing 2026-05-08T10:02:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yarmouk-university-secures-u-s-patent-for-solvent-free-dry-coating-technology-in-pharmaceutical-manufacturing 2026-05-08T10:02:06+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-advances-mrna-hantavirus-vaccine-development-as-deadly-cruise-ship-outbreak-highlights-urgent-medical-need 2026-05-08T10:01:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-advances-mrna-hantavirus-vaccine-development-as-deadly-cruise-ship-outbreak-highlights-urgent-medical-need 2026-05-08T10:01:43+00:00 hourly 0.9 https://trial.medpath.com/news/mexico-amends-health-supplies-regulations-patent-term-compensation-and-data-exclusivity-now-in-effect 2026-05-08T10:01:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mexico-amends-health-supplies-regulations-patent-term-compensation-and-data-exclusivity-now-in-effect 2026-05-08T10:01:29+00:00 hourly 0.9 https://trial.medpath.com/news/fujifilm-receives-japan-approval-for-first-in-class-stem-cell-therapy-for-meniscal-injuries 2026-05-08T09:57:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fujifilm-receives-japan-approval-for-first-in-class-stem-cell-therapy-for-meniscal-injuries 2026-05-08T09:57:24+00:00 hourly 0.9 https://trial.medpath.com/news/chance-pharma-receives-nmpa-acceptance-for-novel-asthma-treatment-cxg87-following-positive-phase-iii-trial 2026-05-08T05:05:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chance-pharma-receives-nmpa-acceptance-for-novel-asthma-treatment-cxg87-following-positive-phase-iii-trial 2026-05-08T05:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/tocilizumab-shows-promise-as-first-potential-treatment-for-deadly-hantavirus-infections 2026-05-08T01:11:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tocilizumab-shows-promise-as-first-potential-treatment-for-deadly-hantavirus-infections 2026-05-08T01:11:52+00:00 hourly 0.9 https://trial.medpath.com/news/mainehealth-and-tufts-launch-expanded-chronic-lyme-study-to-uncover-causes-of-persistent-symptoms 2026-05-07T21:17:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mainehealth-and-tufts-launch-expanded-chronic-lyme-study-to-uncover-causes-of-persistent-symptoms 2026-05-07T21:17:13+00:00 hourly 0.9 https://trial.medpath.com/news/smartcella-expands-extroducer-r-licensing-portfolio-with-heqet-and-oloker-partnerships-for-cardiac-regeneration-and-refractory-angina 2026-05-07T21:14:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smartcella-expands-extroducer-r-licensing-portfolio-with-heqet-and-oloker-partnerships-for-cardiac-regeneration-and-refractory-angina 2026-05-07T21:14:37+00:00 hourly 0.9 https://trial.medpath.com/news/mainehealth-receives-2m-to-establish-maine-s-first-clinical-research-unit-at-biddeford-hospital 2026-05-07T21:05:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mainehealth-receives-2m-to-establish-maine-s-first-clinical-research-unit-at-biddeford-hospital 2026-05-07T21:05:26+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-receives-multiple-buy-ratings-despite-insider-selling-activity-following-strong-q1-2024-financial-performance 2026-05-07T20:55:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incyte-receives-multiple-buy-ratings-despite-insider-selling-activity-following-strong-q1-2024-financial-performance 2026-05-07T20:55:00+00:00 hourly 0.9 https://trial.medpath.com/news/andes-hantavirus-outbreak-on-cruise-ship-who-confirms-human-to-human-transmission-three-dead 2026-05-07T17:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/andes-hantavirus-outbreak-on-cruise-ship-who-confirms-human-to-human-transmission-three-dead 2026-05-07T17:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/parcelbio-emerges-from-stealth-with-13m-to-advance-durable-mrna-platform-for-chronic-diseases 2026-05-07T17:33:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/parcelbio-emerges-from-stealth-with-13m-to-advance-durable-mrna-platform-for-chronic-diseases 2026-05-07T17:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/fujifilm-develops-novel-screening-platform-for-cyclic-peptides-targeting-challenging-membrane-proteins 2026-05-07T17:18:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fujifilm-develops-novel-screening-platform-for-cyclic-peptides-targeting-challenging-membrane-proteins 2026-05-07T17:18:20+00:00 hourly 0.9 https://trial.medpath.com/news/sk-pharmteco-partners-with-nih-and-axle-informatics-to-advance-rare-disease-gene-therapies 2026-05-07T17:14:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sk-pharmteco-partners-with-nih-and-axle-informatics-to-advance-rare-disease-gene-therapies 2026-05-07T17:14:02+00:00 hourly 0.9 https://trial.medpath.com/news/blackstone-invests-250-million-in-anagram-therapeutics-to-advance-novel-enzyme-therapy-for-pancreatic-insufficiency 2026-05-07T17:13:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blackstone-invests-250-million-in-anagram-therapeutics-to-advance-novel-enzyme-therapy-for-pancreatic-insufficiency 2026-05-07T17:13:48+00:00 hourly 0.9 https://trial.medpath.com/news/milliporesigma-secures-exclusive-five-year-testing-agreement-for-genetix-biotherapeutics-fda-approved-gene-therapies 2026-05-07T17:11:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/milliporesigma-secures-exclusive-five-year-testing-agreement-for-genetix-biotherapeutics-fda-approved-gene-therapies 2026-05-07T17:11:12+00:00 hourly 0.9 https://trial.medpath.com/news/altasciences-and-certara-form-strategic-partnership-to-accelerate-early-phase-drug-development 2026-05-07T17:09:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/altasciences-and-certara-form-strategic-partnership-to-accelerate-early-phase-drug-development 2026-05-07T17:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/scarlet-therapeutics-achieves-breakthrough-with-lab-grown-universal-red-blood-cells-matching-donor-cell-survival 2026-05-07T17:08:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scarlet-therapeutics-achieves-breakthrough-with-lab-grown-universal-red-blood-cells-matching-donor-cell-survival 2026-05-07T17:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/neuland-laboratories-partners-with-lir-life-sciences-to-develop-transdermal-glp-1-obesity-treatment 2026-05-07T09:07:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuland-laboratories-partners-with-lir-life-sciences-to-develop-transdermal-glp-1-obesity-treatment 2026-05-07T09:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-s-investigational-pet-tracer-i-124-evuzamitide-meets-primary-endpoints-in-phase-iii-cardiac-amyloidosis-study 2026-05-07T09:07:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-s-investigational-pet-tracer-i-124-evuzamitide-meets-primary-endpoints-in-phase-iii-cardiac-amyloidosis-study 2026-05-07T09:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-expands-strategic-alliance-with-cancer-research-uk-to-accelerate-novel-cancer-therapy-development 2026-05-07T09:04:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucb-expands-strategic-alliance-with-cancer-research-uk-to-accelerate-novel-cancer-therapy-development 2026-05-07T09:04:37+00:00 hourly 0.9 https://trial.medpath.com/news/nona-biosciences-appoints-dr-josh-xiao-as-chief-scientific-officer-to-advance-ai-driven-drug-discovery-platform 2026-05-07T09:04:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nona-biosciences-appoints-dr-josh-xiao-as-chief-scientific-officer-to-advance-ai-driven-drug-discovery-platform 2026-05-07T09:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/largest-blood-protein-genetics-study-reveals-new-precision-medicine-opportunities-including-tyk2-inhibitor-repurposing-for-rheumatoid-arthritis 2026-05-07T05:05:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/largest-blood-protein-genetics-study-reveals-new-precision-medicine-opportunities-including-tyk2-inhibitor-repurposing-for-rheumatoid-arthritis 2026-05-07T05:05:15+00:00 hourly 0.9 https://trial.medpath.com/news/beone-medicines-reports-strong-q1-performance-with-brukinsa-leading-growth-and-pipeline-advances 2026-05-07T01:06:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beone-medicines-reports-strong-q1-performance-with-brukinsa-leading-growth-and-pipeline-advances 2026-05-07T01:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/novel-gene-therapy-and-dna-vaccine-approaches-show-promise-for-functional-hiv-cure 2026-05-07T01:04:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-gene-therapy-and-dna-vaccine-approaches-show-promise-for-functional-hiv-cure 2026-05-07T01:04:54+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-secures-german-reimbursement-for-crispr-gene-therapy-casgevy-in-sickle-cell-disease-and-beta-thalassemia 2026-05-07T01:04:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-secures-german-reimbursement-for-crispr-gene-therapy-casgevy-in-sickle-cell-disease-and-beta-thalassemia 2026-05-07T01:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/image-analysis-group-and-heartcor-solutions-form-strategic-partnership-to-streamline-clinical-trial-cardiac-safety-and-imaging-services 2026-05-07T01:04:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/image-analysis-group-and-heartcor-solutions-form-strategic-partnership-to-streamline-clinical-trial-cardiac-safety-and-imaging-services 2026-05-07T01:04:51+00:00 hourly 0.9 https://trial.medpath.com/news/lqr-house-partners-with-hangzhou-gsy-biotechnology-to-develop-functional-wellness-beverages-using-proprietary-fermentation-technology 2026-05-07T01:04:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lqr-house-partners-with-hangzhou-gsy-biotechnology-to-develop-functional-wellness-beverages-using-proprietary-fermentation-technology 2026-05-07T01:04:14+00:00 hourly 0.9 https://trial.medpath.com/news/kanvas-biosciences-raises-48m-series-a-to-advance-microbiome-based-cancer-immunotherapy 2026-05-07T01:03:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kanvas-biosciences-raises-48m-series-a-to-advance-microbiome-based-cancer-immunotherapy 2026-05-07T01:03:55+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-enhanced-dosing-options-for-crysvita-in-adults-with-x-linked-hypophosphatemia 2026-05-06T21:06:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-enhanced-dosing-options-for-crysvita-in-adults-with-x-linked-hypophosphatemia 2026-05-06T21:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/first-blood-test-to-map-the-tumor-microenvironment-unveiled-by-stanford-and-mayo-clinic-researchers 2026-05-06T21:06:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-blood-test-to-map-the-tumor-microenvironment-unveiled-by-stanford-and-mayo-clinic-researchers 2026-05-06T21:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/novavax-beats-q1-revenue-estimates-as-licensing-strategy-drives-growth-amid-covid-vaccine-demand-decline 2026-05-06T21:05:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novavax-beats-q1-revenue-estimates-as-licensing-strategy-drives-growth-amid-covid-vaccine-demand-decline 2026-05-06T21:05:31+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-withdraws-diabetes-drug-teplizumab-from-fda-fast-track-review-amid-safety-concerns 2026-05-06T21:04:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-withdraws-diabetes-drug-teplizumab-from-fda-fast-track-review-amid-safety-concerns 2026-05-06T21:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-invests-additional-4-5b-in-indiana-manufacturing-opens-first-genetic-medicine-facility 2026-05-06T17:11:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-invests-additional-4-5b-in-indiana-manufacturing-opens-first-genetic-medicine-facility 2026-05-06T17:11:24+00:00 hourly 0.9 https://trial.medpath.com/news/lobe-sciences-advances-l-130-for-chronic-cluster-headache-and-s-100-for-sickle-cell-disease-targets-late-2026-ind-filing 2026-05-06T17:10:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lobe-sciences-advances-l-130-for-chronic-cluster-headache-and-s-100-for-sickle-cell-disease-targets-late-2026-ind-filing 2026-05-06T17:10:32+00:00 hourly 0.9 https://trial.medpath.com/news/ltz-therapeutics-secures-38-million-to-advance-universal-myeloid-cell-engager-immunotherapy-platform 2026-05-06T17:08:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ltz-therapeutics-secures-38-million-to-advance-universal-myeloid-cell-engager-immunotherapy-platform 2026-05-06T17:08:45+00:00 hourly 0.9 https://trial.medpath.com/news/abli-therapeutics-strengthens-board-with-neurodegeneration-expert-dr-rachelle-doody-ahead-of-phase-3-trials 2026-05-06T17:06:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abli-therapeutics-strengthens-board-with-neurodegeneration-expert-dr-rachelle-doody-ahead-of-phase-3-trials 2026-05-06T17:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/upc-central-division-revokes-chinese-military-medical-institute-s-remdesivir-patent-in-landmark-inventive-step-ruling 2026-05-06T17:06:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/upc-central-division-revokes-chinese-military-medical-institute-s-remdesivir-patent-in-landmark-inventive-step-ruling 2026-05-06T17:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/magnesium-channel-blocker-cpacc-reverses-obesity-and-fatty-liver-disease-in-mice-on-western-diet 2026-05-06T17:06:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/magnesium-channel-blocker-cpacc-reverses-obesity-and-fatty-liver-disease-in-mice-on-western-diet 2026-05-06T17:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/cdt-advances-myeloperoxidase-inhibitor-azd5904-into-global-patent-phase-for-male-infertility-treatment 2026-05-06T17:06:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdt-advances-myeloperoxidase-inhibitor-azd5904-into-global-patent-phase-for-male-infertility-treatment 2026-05-06T17:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/scienture-secures-third-patent-for-arbli-losartan-oral-suspension-extending-market-exclusivity-through-2041 2026-05-06T17:05:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scienture-secures-third-patent-for-arbli-losartan-oral-suspension-extending-market-exclusivity-through-2041 2026-05-06T17:05:57+00:00 hourly 0.9 https://trial.medpath.com/news/pathos-ai-acquires-majority-stake-in-deuteroncology-to-advance-ai-identified-met-inhibitor-do-2 2026-05-06T17:05:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pathos-ai-acquires-majority-stake-in-deuteroncology-to-advance-ai-identified-met-inhibitor-do-2 2026-05-06T17:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/infant-bacterial-therapeutics-advances-toward-fda-approval-for-ibp-9414-in-premature-infants 2026-05-06T17:05:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/infant-bacterial-therapeutics-advances-toward-fda-approval-for-ibp-9414-in-premature-infants 2026-05-06T17:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/russia-s-biocad-initiates-phase-iii-trial-of-kadcyla-biosimilar-bcd-237-for-her2-positive-breast-cancer 2026-05-06T17:05:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/russia-s-biocad-initiates-phase-iii-trial-of-kadcyla-biosimilar-bcd-237-for-her2-positive-breast-cancer 2026-05-06T17:05:17+00:00 hourly 0.9 https://trial.medpath.com/news/testosterone-suppresses-glioblastoma-growth-in-males-nih-funded-study-finds 2026-05-06T17:04:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/testosterone-suppresses-glioblastoma-growth-in-males-nih-funded-study-finds 2026-05-06T17:04:04+00:00 hourly 0.9 https://trial.medpath.com/news/fda-launches-one-day-inspection-pilot-using-ai-to-target-low-risk-manufacturing-facilities 2026-05-06T17:04:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-launches-one-day-inspection-pilot-using-ai-to-target-low-risk-manufacturing-facilities 2026-05-06T17:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/ontario-lowers-colorectal-cancer-screening-age-to-45-joining-prince-edward-island-in-landmark-policy-shift 2026-05-06T14:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ontario-lowers-colorectal-cancer-screening-age-to-45-joining-prince-edward-island-in-landmark-policy-shift 2026-05-06T14:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/inmune-bio-achieves-commercial-ready-manufacturing-for-cordstromtm-platform-paving-way-for-global-regulatory-filings-in-rdeb 2026-05-06T13:05:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inmune-bio-achieves-commercial-ready-manufacturing-for-cordstromtm-platform-paving-way-for-global-regulatory-filings-in-rdeb 2026-05-06T13:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-acquires-perfuse-therapeutics-for-2-45-billion-to-advance-novel-glaucoma-and-diabetic-retinopathy-treatment 2026-05-06T13:05:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-acquires-perfuse-therapeutics-for-2-45-billion-to-advance-novel-glaucoma-and-diabetic-retinopathy-treatment 2026-05-06T13:05:22+00:00 hourly 0.9 https://trial.medpath.com/news/tissue-dynamics-and-galmed-partner-to-develop-novel-cardiac-fibrosis-platform-using-human-organoids-and-ai 2026-05-06T13:05:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tissue-dynamics-and-galmed-partner-to-develop-novel-cardiac-fibrosis-platform-using-human-organoids-and-ai 2026-05-06T13:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/fujifilm-biosciences-and-nextcell-launch-commercial-msc-research-platform-to-address-cell-therapy-development-challenges 2026-05-06T13:04:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fujifilm-biosciences-and-nextcell-launch-commercial-msc-research-platform-to-address-cell-therapy-development-challenges 2026-05-06T13:04:59+00:00 hourly 0.9 https://trial.medpath.com/news/908-devices-acquires-nirlab-ag-to-strengthen-narcotics-detection-capabilities 2026-05-06T11:12:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/908-devices-acquires-nirlab-ag-to-strengthen-narcotics-detection-capabilities 2026-05-06T11:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/immutrin-appoints-cardiovascular-expert-dr-robert-blaustein-as-cmo-to-advance-amyloidosis-therapy 2026-05-06T09:04:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immutrin-appoints-cardiovascular-expert-dr-robert-blaustein-as-cmo-to-advance-amyloidosis-therapy 2026-05-06T09:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/andes-hantavirus-outbreak-on-antarctic-cruise-ship-global-public-health-response-and-clinical-updates 2026-05-06T08:47:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/andes-hantavirus-outbreak-on-antarctic-cruise-ship-global-public-health-response-and-clinical-updates 2026-05-06T08:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/mingmed-biotechnology-s-qa102-shows-promise-in-phase-ii-trial-for-intermediate-dry-amd 2026-05-06T05:04:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mingmed-biotechnology-s-qa102-shows-promise-in-phase-ii-trial-for-intermediate-dry-amd 2026-05-06T05:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/zyus-life-sciences-secures-second-u-s-patent-for-cannabichromene-based-pain-management-therapy 2026-05-06T01:05:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zyus-life-sciences-secures-second-u-s-patent-for-cannabichromene-based-pain-management-therapy 2026-05-06T01:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-blocks-publication-of-studies-finding-covid-19-and-shingles-vaccines-safe 2026-05-06T01:05:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-blocks-publication-of-studies-finding-covid-19-and-shingles-vaccines-safe 2026-05-06T01:05:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-authorizes-first-fruit-flavored-e-cigarettes-for-adult-smokers-in-policy-shift 2026-05-06T01:04:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-authorizes-first-fruit-flavored-e-cigarettes-for-adult-smokers-in-policy-shift 2026-05-06T01:04:29+00:00 hourly 0.9 https://trial.medpath.com/news/mammaprint-genomic-profiling-predicts-anthracycline-benefit-in-hr-her2-early-breast-cancer-guiding-nccn-guideline-update 2026-05-05T22:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mammaprint-genomic-profiling-predicts-anthracycline-benefit-in-hr-her2-early-breast-cancer-guiding-nccn-guideline-update 2026-05-05T22:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/vectorbuilder-secures-european-patent-for-minivectm-plasmid-system-advancing-gene-therapy-manufacturing 2026-05-05T21:17:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vectorbuilder-secures-european-patent-for-minivectm-plasmid-system-advancing-gene-therapy-manufacturing 2026-05-05T21:17:41+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-s-ottava-robotic-system-meets-primary-endpoints-in-gastric-bypass-surgery-trial 2026-05-05T21:13:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-j-s-ottava-robotic-system-meets-primary-endpoints-in-gastric-bypass-surgery-trial 2026-05-05T21:13:06+00:00 hourly 0.9 https://trial.medpath.com/news/cvs-health-drops-j-j-s-stelara-from-main-formularies-in-favor-of-lower-cost-biosimilars 2026-05-05T17:10:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cvs-health-drops-j-j-s-stelara-from-main-formularies-in-favor-of-lower-cost-biosimilars 2026-05-05T17:10:25+00:00 hourly 0.9 https://trial.medpath.com/news/tris-pharma-launches-adneuris-therapeutics-to-advance-first-in-class-dual-nmr-agonist-cebranopadol-for-moderate-to-severe-acute-pain 2026-05-05T17:10:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tris-pharma-launches-adneuris-therapeutics-to-advance-first-in-class-dual-nmr-agonist-cebranopadol-for-moderate-to-severe-acute-pain 2026-05-05T17:10:18+00:00 hourly 0.9 https://trial.medpath.com/news/tegoprazan-demonstrates-superior-healing-and-maintenance-in-phase-3-erosive-esophagitis-trial 2026-05-05T17:10:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tegoprazan-demonstrates-superior-healing-and-maintenance-in-phase-3-erosive-esophagitis-trial 2026-05-05T17:10:09+00:00 hourly 0.9 https://trial.medpath.com/news/dupixent-demonstrates-disease-modifying-effects-in-eosinophilic-esophagitis-phase-4-trial 2026-05-05T17:10:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dupixent-demonstrates-disease-modifying-effects-in-eosinophilic-esophagitis-phase-4-trial 2026-05-05T17:10:02+00:00 hourly 0.9 https://trial.medpath.com/news/myphenome-genetic-test-predicts-weight-loss-outcomes-across-glp-1-and-surgical-obesity-treatments-mayo-clinic-studies-show 2026-05-05T17:09:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/myphenome-genetic-test-predicts-weight-loss-outcomes-across-glp-1-and-surgical-obesity-treatments-mayo-clinic-studies-show 2026-05-05T17:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/mimivax-and-roswell-park-launch-phase-2-trial-of-survaxm-cancer-vaccine-for-metastatic-neuroendocrine-tumors 2026-05-05T17:07:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mimivax-and-roswell-park-launch-phase-2-trial-of-survaxm-cancer-vaccine-for-metastatic-neuroendocrine-tumors 2026-05-05T17:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/non-viral-gene-therapies-gain-momentum-as-safety-concerns-drive-industry-shift-from-viral-vectors 2026-05-05T17:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/non-viral-gene-therapies-gain-momentum-as-safety-concerns-drive-industry-shift-from-viral-vectors 2026-05-05T17:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/viralgen-partners-with-elaaj-bio-to-advance-gene-therapy-for-rare-pediatric-disorder-cdkl5-deficiency 2026-05-05T17:07:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viralgen-partners-with-elaaj-bio-to-advance-gene-therapy-for-rare-pediatric-disorder-cdkl5-deficiency 2026-05-05T17:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-to-close-german-manufacturing-site-in-wehr-by-2028-affecting-220-jobs 2026-05-05T17:06:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-to-close-german-manufacturing-site-in-wehr-by-2028-affecting-220-jobs 2026-05-05T17:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/transcelerate-and-fda-collaborate-on-streamlined-safety-data-collection-to-advance-pragmatic-clinical-trials 2026-05-05T17:04:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transcelerate-and-fda-collaborate-on-streamlined-safety-data-collection-to-advance-pragmatic-clinical-trials 2026-05-05T17:04:15+00:00 hourly 0.9 https://trial.medpath.com/news/anteris-technologies-initiates-u-s-enrollment-in-paradigm-trial-for-novel-biomimetic-heart-valve 2026-05-05T17:04:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anteris-technologies-initiates-u-s-enrollment-in-paradigm-trial-for-novel-biomimetic-heart-valve 2026-05-05T17:04:04+00:00 hourly 0.9 https://trial.medpath.com/news/tissium-secures-up-to-eur60m-financing-to-accelerate-commercial-rollout-of-sutureless-nerve-repair-platform 2026-05-05T13:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tissium-secures-up-to-eur60m-financing-to-accelerate-commercial-rollout-of-sutureless-nerve-repair-platform 2026-05-05T13:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-cs-1103-for-fentanyl-overdose-reversal 2026-05-05T13:10:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-cs-1103-for-fentanyl-overdose-reversal 2026-05-05T13:10:34+00:00 hourly 0.9 https://trial.medpath.com/news/cytospire-raises-83m-series-a-to-advance-novel-gamma-delta-t-cell-engagers-for-cancer-treatment 2026-05-05T09:05:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytospire-raises-83m-series-a-to-advance-novel-gamma-delta-t-cell-engagers-for-cancer-treatment 2026-05-05T09:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-breakthrough-gene-therapy-to-restore-hearing-in-children-born-deaf 2026-05-05T09:05:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-breakthrough-gene-therapy-to-restore-hearing-in-children-born-deaf 2026-05-05T09:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/abivax-repurchases-90-million-in-royalty-certificates-streamlining-capital-structure-ahead-of-obefazimod-commercialization 2026-05-05T09:04:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abivax-repurchases-90-million-in-royalty-certificates-streamlining-capital-structure-ahead-of-obefazimod-commercialization 2026-05-05T09:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/swiss-biotech-sector-achieves-record-revenue-and-38-private-funding-surge-in-2025 2026-05-05T09:04:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/swiss-biotech-sector-achieves-record-revenue-and-38-private-funding-surge-in-2025 2026-05-05T09:04:12+00:00 hourly 0.9 https://trial.medpath.com/news/xbrane-and-intas-revise-financing-terms-for-opdivo-biosimilar-xdivane-development 2026-05-05T09:04:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xbrane-and-intas-revise-financing-terms-for-opdivo-biosimilar-xdivane-development 2026-05-05T09:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/tlx250-px-shows-promise-for-diagnosing-multiple-kidney-cancer-types-beyond-clear-cell-renal-cell-carcinoma 2026-05-05T01:05:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tlx250-px-shows-promise-for-diagnosing-multiple-kidney-cancer-types-beyond-clear-cell-renal-cell-carcinoma 2026-05-05T01:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/recludix-s-oral-stat6-inhibitor-rex-8756-shows-efficacy-comparable-to-monoclonal-antibodies-in-atopic-dermatitis-model 2026-05-04T21:10:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recludix-s-oral-stat6-inhibitor-rex-8756-shows-efficacy-comparable-to-monoclonal-antibodies-in-atopic-dermatitis-model 2026-05-04T21:10:26+00:00 hourly 0.9 https://trial.medpath.com/news/palopegteriparatide-shows-sustained-3-year-benefits-in-hypoparathyroidism-treatment 2026-05-04T21:08:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/palopegteriparatide-shows-sustained-3-year-benefits-in-hypoparathyroidism-treatment 2026-05-04T21:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/proton-beam-therapy-shows-promise-as-noninvasive-treatment-for-refractory-ventricular-tachycardia 2026-05-04T21:08:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proton-beam-therapy-shows-promise-as-noninvasive-treatment-for-refractory-ventricular-tachycardia 2026-05-04T21:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/probio-launches-viral-vector-packaging-test-to-accelerate-cell-and-gene-therapy-development 2026-05-04T21:08:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/probio-launches-viral-vector-packaging-test-to-accelerate-cell-and-gene-therapy-development 2026-05-04T21:08:02+00:00 hourly 0.9 https://trial.medpath.com/news/sgs-acquires-keystone-bioanalytical-to-expand-north-american-drug-development-testing-capabilities 2026-05-04T21:06:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sgs-acquires-keystone-bioanalytical-to-expand-north-american-drug-development-testing-capabilities 2026-05-04T21:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/retroviral-vectors-are-back-can-manufacturing-keep-pace-with-the-cgt-revolution 2026-05-04T21:06:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/retroviral-vectors-are-back-can-manufacturing-keep-pace-with-the-cgt-revolution 2026-05-04T21:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/first-ever-sperm-production-achieved-after-re-transplanting-childhood-frozen-testicular-tissue 2026-05-04T21:05:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-ever-sperm-production-achieved-after-re-transplanting-childhood-frozen-testicular-tissue 2026-05-04T21:05:40+00:00 hourly 0.9 https://trial.medpath.com/news/ctibiotech-launches-us-operations-with-27-million-investment-to-advance-3d-bioprinting-for-drug-development 2026-05-04T21:05:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ctibiotech-launches-us-operations-with-27-million-investment-to-advance-3d-bioprinting-for-drug-development 2026-05-04T21:05:23+00:00 hourly 0.9 https://trial.medpath.com/news/general-proximity-secures-investment-from-freemind-and-daewoong-for-next-generation-induced-proximity-platform 2026-05-04T17:32:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/general-proximity-secures-investment-from-freemind-and-daewoong-for-next-generation-induced-proximity-platform 2026-05-04T17:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/nigeria-targets-30-cancer-burden-reduction-by-2030-explores-car-t-cell-therapy-adoption 2026-05-04T17:29:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nigeria-targets-30-cancer-burden-reduction-by-2030-explores-car-t-cell-therapy-adoption 2026-05-04T17:29:48+00:00 hourly 0.9 https://trial.medpath.com/news/latus-bio-secures-97m-series-a-to-advance-gene-therapy-pipeline-for-neurodegenerative-diseases 2026-05-04T17:29:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/latus-bio-secures-97m-series-a-to-advance-gene-therapy-pipeline-for-neurodegenerative-diseases 2026-05-04T17:29:11+00:00 hourly 0.9 https://trial.medpath.com/news/kubota-vision-partners-with-laboratoires-kol-to-provide-emixustat-for-stargardt-disease-under-compassionate-use-in-france 2026-05-04T17:29:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kubota-vision-partners-with-laboratoires-kol-to-provide-emixustat-for-stargardt-disease-under-compassionate-use-in-france 2026-05-04T17:29:08+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-asceniv-label-to-include-pediatric-patients-as-young-as-two-years-for-primary-immunodeficiency-treatment 2026-05-04T17:28:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-asceniv-label-to-include-pediatric-patients-as-young-as-two-years-for-primary-immunodeficiency-treatment 2026-05-04T17:28:55+00:00 hourly 0.9 https://trial.medpath.com/news/windward-bio-secures-165m-to-advance-ultra-long-acting-immunology-therapies-for-asthma-and-copd 2026-05-04T17:27:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/windward-bio-secures-165m-to-advance-ultra-long-acting-immunology-therapies-for-asthma-and-copd 2026-05-04T17:27:09+00:00 hourly 0.9 https://trial.medpath.com/news/caplyta-shows-superior-efficacy-among-adjunctive-depression-treatments-in-first-network-meta-analysis 2026-05-04T17:27:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caplyta-shows-superior-efficacy-among-adjunctive-depression-treatments-in-first-network-meta-analysis 2026-05-04T17:27:03+00:00 hourly 0.9 https://trial.medpath.com/news/decentralized-clinical-trials-fda-and-ema-guidance-highlights-strategic-value-of-hybrid-designs-over-fully-virtual-models 2026-05-04T17:26:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/decentralized-clinical-trials-fda-and-ema-guidance-highlights-strategic-value-of-hybrid-designs-over-fully-virtual-models 2026-05-04T17:26:50+00:00 hourly 0.9 https://trial.medpath.com/news/istios-health-partners-with-care-id-to-bridge-clinical-trial-access-gap-in-infectious-disease-research 2026-05-04T13:05:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/istios-health-partners-with-care-id-to-bridge-clinical-trial-access-gap-in-infectious-disease-research 2026-05-04T13:05:36+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-biosciences-initiates-phase-1-trial-for-novel-crf2-agonist-nbip-2118-in-obesity-treatment 2026-05-04T13:04:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurocrine-biosciences-initiates-phase-1-trial-for-novel-crf2-agonist-nbip-2118-in-obesity-treatment 2026-05-04T13:04:45+00:00 hourly 0.9 https://trial.medpath.com/news/sunshine-lake-pharma-becomes-first-chinese-company-to-secure-fda-approval-for-insulin-glargine-in-us-market 2026-05-04T13:04:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sunshine-lake-pharma-becomes-first-chinese-company-to-secure-fda-approval-for-insulin-glargine-in-us-market 2026-05-04T13:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/grin-therapeutics-expands-phase-3-beeline-trial-to-europe-for-rare-neurodevelopmental-disorder-treatment 2026-05-04T13:04:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grin-therapeutics-expands-phase-3-beeline-trial-to-europe-for-rare-neurodevelopmental-disorder-treatment 2026-05-04T13:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/rose-bengal-sodium-shows-light-independent-activity-against-mrsa-and-biofilms-in-new-u-s-patent-expanding-visirose-s-ophthalmic-pipeline 2026-05-04T12:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rose-bengal-sodium-shows-light-independent-activity-against-mrsa-and-biofilms-in-new-u-s-patent-expanding-visirose-s-ophthalmic-pipeline 2026-05-04T12:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/kwangdong-pharmaceutical-secures-first-generic-exclusivity-for-tagrisso-joining-chong-kun-dang-in-race-for-korea-s-krw-110-billion-nsclc-market 2026-05-04T09:04:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kwangdong-pharmaceutical-secures-first-generic-exclusivity-for-tagrisso-joining-chong-kun-dang-in-race-for-korea-s-krw-110-billion-nsclc-market 2026-05-04T09:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/low-dose-endoxifen-shows-promise-for-breast-cancer-prevention-with-reduced-side-effects 2026-05-04T09:04:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/low-dose-endoxifen-shows-promise-for-breast-cancer-prevention-with-reduced-side-effects 2026-05-04T09:04:39+00:00 hourly 0.9 https://trial.medpath.com/news/evotec-and-almirall-advance-first-dermatology-drug-candidate-in-record-time-using-ai-driven-platform 2026-05-04T09:04:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evotec-and-almirall-advance-first-dermatology-drug-candidate-in-record-time-using-ai-driven-platform 2026-05-04T09:04:02+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-acquires-candid-therapeutics-for-2-2-billion-advancing-t-cell-engager-platform-for-autoimmune-diseases 2026-05-04T09:03:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucb-acquires-candid-therapeutics-for-2-2-billion-advancing-t-cell-engager-platform-for-autoimmune-diseases 2026-05-04T09:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/b-braun-launches-first-fda-approved-room-temperature-stable-rocuronium-bromide-prefilled-syringe 2026-05-04T08:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/b-braun-launches-first-fda-approved-room-temperature-stable-rocuronium-bromide-prefilled-syringe 2026-05-04T08:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-mrna-lnp-cancer-therapy-harnesses-pre-existing-measles-immunity-to-enhance-tumor-killing-cd8-t-cells 2026-05-04T05:05:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-mrna-lnp-cancer-therapy-harnesses-pre-existing-measles-immunity-to-enhance-tumor-killing-cd8-t-cells 2026-05-04T05:05:27+00:00 hourly 0.9 https://trial.medpath.com/news/futurechem-receives-korean-approval-for-prostaview-prostate-cancer-diagnostic-marking-second-global-psma-pet-agent 2026-05-04T05:04:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/futurechem-receives-korean-approval-for-prostaview-prostate-cancer-diagnostic-marking-second-global-psma-pet-agent 2026-05-04T05:04:23+00:00 hourly 0.9 https://trial.medpath.com/news/d-d-pharmatech-raises-165m-as-mash-drug-dd01-approaches-key-phase-2-readout 2026-05-04T05:03:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/d-d-pharmatech-raises-165m-as-mash-drug-dd01-approaches-key-phase-2-readout 2026-05-04T05:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/novelty-nobility-expands-partnership-with-agc-biologics-for-first-in-class-bispecific-antibody-nn4101 2026-05-04T05:03:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novelty-nobility-expands-partnership-with-agc-biologics-for-first-in-class-bispecific-antibody-nn4101 2026-05-04T05:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/psilocybin-assisted-therapy-achieves-75-response-rate-in-treatment-resistant-ibs-patients 2026-05-04T05:03:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psilocybin-assisted-therapy-achieves-75-response-rate-in-treatment-resistant-ibs-patients 2026-05-04T05:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/xtalpi-enabled-prmt5-inhibitor-pep08-reaches-phase-i-enrollment-milestone-in-solid-tumor-trial 2026-05-04T05:03:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xtalpi-enabled-prmt5-inhibitor-pep08-reaches-phase-i-enrollment-milestone-in-solid-tumor-trial 2026-05-04T05:03:52+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-drugs-drive-pharma-r-d-returns-to-7-as-obesity-overtakes-oncology-in-pipeline-value 2026-05-04T05:03:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-drugs-drive-pharma-r-d-returns-to-7-as-obesity-overtakes-oncology-in-pipeline-value 2026-05-04T05:03:51+00:00 hourly 0.9 https://trial.medpath.com/news/prometheus-laboratories-advances-next-generation-blood-test-for-mash-patient-identification 2026-05-03T21:04:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prometheus-laboratories-advances-next-generation-blood-test-for-mash-patient-identification 2026-05-03T21:04:27+00:00 hourly 0.9 https://trial.medpath.com/news/everads-therapy-reports-positive-first-in-human-data-for-novel-suprachoroidal-drug-delivery-system-in-diabetic-macular-edema 2026-05-03T17:04:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/everads-therapy-reports-positive-first-in-human-data-for-novel-suprachoroidal-drug-delivery-system-in-diabetic-macular-edema 2026-05-03T17:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/nice-approves-ucb-s-rystiggo-for-myasthenia-gravis-treatment-on-nhs-in-england 2026-05-03T13:03:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-approves-ucb-s-rystiggo-for-myasthenia-gravis-treatment-on-nhs-in-england 2026-05-03T13:03:51+00:00 hourly 0.9 https://trial.medpath.com/news/certara-and-nvidia-partner-to-bring-ai-powered-autonomous-agents-to-drug-development 2026-05-03T09:04:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/certara-and-nvidia-partner-to-bring-ai-powered-autonomous-agents-to-drug-development 2026-05-03T09:04:17+00:00 hourly 0.9 https://trial.medpath.com/news/minimal-residual-disease-pipeline-set-for-strategic-expansion-by-2026-with-emerging-immunotherapies-and-precision-diagnostics 2026-05-02T21:06:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/minimal-residual-disease-pipeline-set-for-strategic-expansion-by-2026-with-emerging-immunotherapies-and-precision-diagnostics 2026-05-02T21:06:14+00:00 hourly 0.9 https://trial.medpath.com/news/sglt2-inhibitors-show-promise-in-reducing-heart-transplant-rejection-risk-in-diabetic-patients 2026-05-02T21:05:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sglt2-inhibitors-show-promise-in-reducing-heart-transplant-rejection-risk-in-diabetic-patients 2026-05-02T21:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/liquid-biopsy-blood-tests-predict-breast-cancer-immunotherapy-response-in-vanderbilt-study 2026-05-02T21:05:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liquid-biopsy-blood-tests-predict-breast-cancer-immunotherapy-response-in-vanderbilt-study 2026-05-02T21:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-confirms-blinatumomab-effectiveness-as-bridge-to-transplant-in-b-cell-precursor-all 2026-05-02T21:04:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-confirms-blinatumomab-effectiveness-as-bridge-to-transplant-in-b-cell-precursor-all 2026-05-02T21:04:54+00:00 hourly 0.9 https://trial.medpath.com/news/inspiremd-receives-fda-approval-for-cguardians-iii-pivotal-study-of-switchguard-neuro-protection-system 2026-05-02T21:04:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inspiremd-receives-fda-approval-for-cguardians-iii-pivotal-study-of-switchguard-neuro-protection-system 2026-05-02T21:04:41+00:00 hourly 0.9 https://trial.medpath.com/news/novel-conditioning-regimen-achieves-100-2-year-survival-in-sickle-cell-transplant-study 2026-05-02T17:06:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-conditioning-regimen-achieves-100-2-year-survival-in-sickle-cell-transplant-study 2026-05-02T17:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/billiontoone-launches-unity-confirm-non-invasive-fetal-cell-test-bridges-gap-between-screening-and-invasive-diagnostics 2026-05-02T17:05:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/billiontoone-launches-unity-confirm-non-invasive-fetal-cell-test-bridges-gap-between-screening-and-invasive-diagnostics 2026-05-02T17:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/bytedance-s-anew-labs-presents-first-ai-designed-therapy-targeting-previously-undruggable-il-17-protein 2026-05-02T13:05:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bytedance-s-anew-labs-presents-first-ai-designed-therapy-targeting-previously-undruggable-il-17-protein 2026-05-02T13:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/convergent-evolution-in-aplastic-anemia-independent-hla-loss-clones-drive-remission-without-increasing-leukemia-risk 2026-05-02T13:05:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/convergent-evolution-in-aplastic-anemia-independent-hla-loss-clones-drive-remission-without-increasing-leukemia-risk 2026-05-02T13:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/mayo-clinic-ai-model-detects-pancreatic-cancer-nearly-3-years-before-clinical-diagnosis 2026-05-02T09:05:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mayo-clinic-ai-model-detects-pancreatic-cancer-nearly-3-years-before-clinical-diagnosis 2026-05-02T09:05:34+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-reveals-lower-hyperglycemia-management-burden-with-capivasertib-versus-alpelisib-in-metastatic-breast-cancer 2026-05-02T09:04:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-reveals-lower-hyperglycemia-management-burden-with-capivasertib-versus-alpelisib-in-metastatic-breast-cancer 2026-05-02T09:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/sonire-therapeutics-launches-first-u-s-clinical-trial-of-ultrasound-guided-hifu-for-pancreatic-cancer 2026-05-02T01:06:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sonire-therapeutics-launches-first-u-s-clinical-trial-of-ultrasound-guided-hifu-for-pancreatic-cancer 2026-05-02T01:06:13+00:00 hourly 0.9 https://trial.medpath.com/news/antibiotic-minocycline-shows-promise-as-novel-treatment-for-panic-disorder-in-clinical-trial 2026-05-02T01:05:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antibiotic-minocycline-shows-promise-as-novel-treatment-for-panic-disorder-in-clinical-trial 2026-05-02T01:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/sparc-sells-rare-pediatric-disease-priority-review-voucher-for-195-million-following-sezaby-approval 2026-05-02T01:05:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sparc-sells-rare-pediatric-disease-priority-review-voucher-for-195-million-following-sezaby-approval 2026-05-02T01:05:13+00:00 hourly 0.9 https://trial.medpath.com/news/iterative-health-secures-77m-series-c-to-expand-ai-powered-clinical-trial-network 2026-05-02T01:05:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iterative-health-secures-77m-series-c-to-expand-ai-powered-clinical-trial-network 2026-05-02T01:05:09+00:00 hourly 0.9 https://trial.medpath.com/news/summit-therapeutics-cancels-500m-share-sale-amid-ivonescimab-data-debate 2026-05-01T22:34:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/summit-therapeutics-cancels-500m-share-sale-amid-ivonescimab-data-debate 2026-05-01T22:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-protac-drug-veppanu-for-esr1-mutated-breast-cancer 2026-05-01T22:34:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-protac-drug-veppanu-for-esr1-mutated-breast-cancer 2026-05-01T22:34:10+00:00 hourly 0.9 https://trial.medpath.com/news/weill-cornell-researchers-reverse-engineer-ketamine-s-antidepressant-mechanism-paving-way-for-safer-alternatives 2026-05-01T22:34:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/weill-cornell-researchers-reverse-engineer-ketamine-s-antidepressant-mechanism-paving-way-for-safer-alternatives 2026-05-01T22:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/lakewood-amedex-reports-low-resistance-development-for-novel-antimicrobial-nu-3-in-diabetic-foot-ulcer-treatment 2026-05-01T17:06:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lakewood-amedex-reports-low-resistance-development-for-novel-antimicrobial-nu-3-in-diabetic-foot-ulcer-treatment 2026-05-01T17:06:32+00:00 hourly 0.9 https://trial.medpath.com/news/biovaxys-mri-study-validates-immune-response-mechanism-of-mvp-s-combination-therapy-in-ovarian-cancer 2026-05-01T17:05:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biovaxys-mri-study-validates-immune-response-mechanism-of-mvp-s-combination-therapy-in-ovarian-cancer 2026-05-01T17:05:42+00:00 hourly 0.9 https://trial.medpath.com/news/us-maintains-pressure-on-india-s-pharmaceutical-patent-system-through-priority-watch-list-designation 2026-05-01T17:05:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-maintains-pressure-on-india-s-pharmaceutical-patent-system-through-priority-watch-list-designation 2026-05-01T17:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/quadruple-immunotherapy-shows-durable-complete-response-in-mss-metastatic-colorectal-cancer-but-lacks-reproducibility 2026-05-01T17:05:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quadruple-immunotherapy-shows-durable-complete-response-in-mss-metastatic-colorectal-cancer-but-lacks-reproducibility 2026-05-01T17:05:08+00:00 hourly 0.9 https://trial.medpath.com/news/corcept-s-dazucorilant-shows-87-reduction-in-death-risk-for-als-patients-despite-missing-primary-endpoint 2026-05-01T13:06:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corcept-s-dazucorilant-shows-87-reduction-in-death-risk-for-als-patients-despite-missing-primary-endpoint 2026-05-01T13:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/ai-model-compass-outperforms-existing-methods-in-predicting-response-to-cancer-immunotherapy 2026-05-01T13:06:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-model-compass-outperforms-existing-methods-in-predicting-response-to-cancer-immunotherapy 2026-05-01T13:06:13+00:00 hourly 0.9 https://trial.medpath.com/news/viatris-presents-positive-phase-3-data-for-low-dose-estrogen-contraceptive-patch-at-acog-2026 2026-05-01T13:05:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viatris-presents-positive-phase-3-data-for-low-dose-estrogen-contraceptive-patch-at-acog-2026 2026-05-01T13:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/immuno-pet-imaging-reveals-body-wide-immune-response-to-oncolytic-virotherapy-in-head-and-neck-cancer 2026-05-01T09:04:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immuno-pet-imaging-reveals-body-wide-immune-response-to-oncolytic-virotherapy-in-head-and-neck-cancer 2026-05-01T09:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/oberland-biotech-secures-chf-2-5-million-seed-funding-to-advance-biotechnology-and-nutritional-food-innovation 2026-05-01T09:03:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oberland-biotech-secures-chf-2-5-million-seed-funding-to-advance-biotechnology-and-nutritional-food-innovation 2026-05-01T09:03:54+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-acquires-imidomics-patient-insight-business-to-advance-precision-medicine-in-immune-mediated-inflammatory-diseases 2026-05-01T09:03:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucb-acquires-imidomics-patient-insight-business-to-advance-precision-medicine-in-immune-mediated-inflammatory-diseases 2026-05-01T09:03:51+00:00 hourly 0.9 https://trial.medpath.com/news/factor-bioscience-advances-il-12-engineered-imacrophage-therapy-for-solid-tumors-with-promising-ovarian-cancer-data 2026-05-01T05:09:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/factor-bioscience-advances-il-12-engineered-imacrophage-therapy-for-solid-tumors-with-promising-ovarian-cancer-data 2026-05-01T05:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/usc-team-maps-spinal-cord-address-for-bladder-control-restoring-voiding-in-91-7-of-trials 2026-05-01T05:09:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/usc-team-maps-spinal-cord-address-for-bladder-control-restoring-voiding-in-91-7-of-trials 2026-05-01T05:09:13+00:00 hourly 0.9 https://trial.medpath.com/news/contineum-therapeutics-reports-positive-phase-1b-results-for-pipe-791-in-chronic-pain-treatment 2026-05-01T05:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/contineum-therapeutics-reports-positive-phase-1b-results-for-pipe-791-in-chronic-pain-treatment 2026-05-01T05:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/cflip-identified-as-novel-therapeutic-vulnerability-in-aggressive-abc-dlbcl-overcoming-treatment-resistance 2026-05-01T05:06:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cflip-identified-as-novel-therapeutic-vulnerability-in-aggressive-abc-dlbcl-overcoming-treatment-resistance 2026-05-01T05:06:25+00:00 hourly 0.9 https://trial.medpath.com/news/nykode-therapeutics-advances-ai-powered-immunotherapy-platform-with-strong-clinical-progress 2026-05-01T05:05:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nykode-therapeutics-advances-ai-powered-immunotherapy-platform-with-strong-clinical-progress 2026-05-01T05:05:03+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-reports-strong-q1-growth-driven-by-cholesterol-drug-advances-weight-loss-drug-maritide-development 2026-05-01T05:03:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-reports-strong-q1-growth-driven-by-cholesterol-drug-advances-weight-loss-drug-maritide-development 2026-05-01T05:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/precision-neuroscience-partners-with-uchicago-medicine-to-advance-brain-computer-interface-research-for-motor-function-restoration 2026-05-01T05:03:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-neuroscience-partners-with-uchicago-medicine-to-advance-brain-computer-interface-research-for-motor-function-restoration 2026-05-01T05:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/northwest-biotherapeutics-appoints-dr-annalisa-jenkins-as-strategic-adviser-to-advance-dendritic-cell-cancer-vaccine-platform 2026-05-01T01:04:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northwest-biotherapeutics-appoints-dr-annalisa-jenkins-as-strategic-adviser-to-advance-dendritic-cell-cancer-vaccine-platform 2026-05-01T01:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/mrm-health-s-mh002-receives-fda-fast-track-designation-for-ulcerative-colitis-treatment 2026-05-01T01:04:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrm-health-s-mh002-receives-fda-fast-track-designation-for-ulcerative-colitis-treatment 2026-05-01T01:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/cannabis-drug-companies-eye-ipos-and-private-funding-following-u-s-rescheduling-to-schedule-iii 2026-04-30T22:54:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cannabis-drug-companies-eye-ipos-and-private-funding-following-u-s-rescheduling-to-schedule-iii 2026-04-30T22:54:44+00:00 hourly 0.9 https://trial.medpath.com/news/arpa-h-awards-siemens-healthineers-60-million-to-develop-ultra-high-speed-photon-flash-radiotherapy 2026-04-30T22:53:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arpa-h-awards-siemens-healthineers-60-million-to-develop-ultra-high-speed-photon-flash-radiotherapy 2026-04-30T22:53:24+00:00 hourly 0.9 https://trial.medpath.com/news/moleculent-secures-20-million-to-advance-cell-communication-mapping-technology 2026-04-30T22:52:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moleculent-secures-20-million-to-advance-cell-communication-mapping-technology 2026-04-30T22:52:17+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-initiates-phase-2-trial-for-novel-non-opioid-pain-therapy-cftx-1554 2026-04-30T22:51:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lilly-initiates-phase-2-trial-for-novel-non-opioid-pain-therapy-cftx-1554 2026-04-30T22:51:30+00:00 hourly 0.9 https://trial.medpath.com/news/discontinuing-oac-after-af-catheter-ablation-reduces-bleeding-without-increasing-stroke-risk-alone-af-trial 2026-04-30T22:50:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/discontinuing-oac-after-af-catheter-ablation-reduces-bleeding-without-increasing-stroke-risk-alone-af-trial 2026-04-30T22:50:43+00:00 hourly 0.9 https://trial.medpath.com/news/engeneic-doses-first-patient-with-novel-egfr-targeted-nanocell-therapy-for-recurrent-glioblastoma 2026-04-30T22:50:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engeneic-doses-first-patient-with-novel-egfr-targeted-nanocell-therapy-for-recurrent-glioblastoma 2026-04-30T22:50:20+00:00 hourly 0.9 https://trial.medpath.com/news/avita-medical-appoints-cary-vance-as-permanent-ceo-following-successful-interim-leadership 2026-04-30T17:09:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avita-medical-appoints-cary-vance-as-permanent-ceo-following-successful-interim-leadership 2026-04-30T17:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/guardant-health-partners-with-nuvalent-in-multi-year-collaboration-for-precision-cancer-diagnostics 2026-04-30T17:06:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/guardant-health-partners-with-nuvalent-in-multi-year-collaboration-for-precision-cancer-diagnostics 2026-04-30T17:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/leo-pharma-acquires-replay-for-50-million-to-advance-hsv-gene-therapy-platform-for-rare-skin-diseases 2026-04-30T17:06:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leo-pharma-acquires-replay-for-50-million-to-advance-hsv-gene-therapy-platform-for-rare-skin-diseases 2026-04-30T17:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/theradaptive-receives-fda-approval-to-advance-osteoadapt-sp-to-pivotal-phase-3-trial-for-spinal-fusion 2026-04-30T17:05:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theradaptive-receives-fda-approval-to-advance-osteoadapt-sp-to-pivotal-phase-3-trial-for-spinal-fusion 2026-04-30T17:05:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-device-designation-to-supraspacer-implant-for-irreparable-rotator-cuff-tears 2026-04-30T17:04:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-device-designation-to-supraspacer-implant-for-irreparable-rotator-cuff-tears 2026-04-30T17:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/stealth-biotherapeutics-reports-strong-early-uptake-for-forzinity-in-barth-syndrome-treatment 2026-04-30T17:04:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stealth-biotherapeutics-reports-strong-early-uptake-for-forzinity-in-barth-syndrome-treatment 2026-04-30T17:04:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-halts-newron-s-phase-iii-schizophrenia-trial-following-patient-death 2026-04-30T13:06:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-halts-newron-s-phase-iii-schizophrenia-trial-following-patient-death 2026-04-30T13:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/orchard-therapeutics-receives-innovation-passport-for-gene-therapy-otl-201-targeting-rare-sanfilippo-syndrome 2026-04-30T13:06:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orchard-therapeutics-receives-innovation-passport-for-gene-therapy-otl-201-targeting-rare-sanfilippo-syndrome 2026-04-30T13:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/redhill-s-rhb-204-shows-comparable-antimicrobial-efficacy-to-rhb-104-in-crohn-s-disease-development 2026-04-30T13:05:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redhill-s-rhb-204-shows-comparable-antimicrobial-efficacy-to-rhb-104-in-crohn-s-disease-development 2026-04-30T13:05:05+00:00 hourly 0.9 https://trial.medpath.com/news/fda-infant-formula-safety-study-finds-low-contaminant-levels-amid-mounting-recall-concerns 2026-04-30T09:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-infant-formula-safety-study-finds-low-contaminant-levels-amid-mounting-recall-concerns 2026-04-30T09:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/evotec-secures-9-9-million-in-gates-foundation-grants-to-advance-next-generation-tuberculosis-therapies 2026-04-30T09:05:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evotec-secures-9-9-million-in-gates-foundation-grants-to-advance-next-generation-tuberculosis-therapies 2026-04-30T09:05:02+00:00 hourly 0.9 https://trial.medpath.com/news/syntara-raises-10-million-to-advance-amsulostat-phase-2b-trial-in-myelofibrosis 2026-04-30T09:04:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/syntara-raises-10-million-to-advance-amsulostat-phase-2b-trial-in-myelofibrosis 2026-04-30T09:04:15+00:00 hourly 0.9 https://trial.medpath.com/news/formosa-pharmaceuticals-partners-with-singapore-eye-research-institute-to-develop-advanced-ophthalmic-formulations 2026-04-30T09:04:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/formosa-pharmaceuticals-partners-with-singapore-eye-research-institute-to-develop-advanced-ophthalmic-formulations 2026-04-30T09:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/livzon-pharmaceutical-receives-regulatory-approval-for-brexpiprazole-microsphere-clinical-trial-in-adult-schizophrenia 2026-04-30T07:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/livzon-pharmaceutical-receives-regulatory-approval-for-brexpiprazole-microsphere-clinical-trial-in-adult-schizophrenia 2026-04-30T07:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/indian-patent-office-rejects-abbvie-patents-for-rinvoq-and-maviret-clearing-path-for-generic-competition 2026-04-30T05:05:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indian-patent-office-rejects-abbvie-patents-for-rinvoq-and-maviret-clearing-path-for-generic-competition 2026-04-30T05:05:07+00:00 hourly 0.9 https://trial.medpath.com/news/parexel-acquires-ai-powered-pharmacovigilance-platform-vitrana-to-enhance-patient-safety-technology 2026-04-30T05:05:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/parexel-acquires-ai-powered-pharmacovigilance-platform-vitrana-to-enhance-patient-safety-technology 2026-04-30T05:05:05+00:00 hourly 0.9 https://trial.medpath.com/news/decade-long-study-reveals-common-knee-surgery-no-better-than-placebo-may-worsen-outcomes 2026-04-30T05:05:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/decade-long-study-reveals-common-knee-surgery-no-better-than-placebo-may-worsen-outcomes 2026-04-30T05:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/novel-radiotracer-shows-promise-for-non-invasive-endometriosis-diagnosis-in-phase-2-trial 2026-04-30T05:04:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-radiotracer-shows-promise-for-non-invasive-endometriosis-diagnosis-in-phase-2-trial 2026-04-30T05:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-exercises-option-for-pinetree-s-first-in-class-egfr-degrader-in-500m-deal 2026-04-30T05:04:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-exercises-option-for-pinetree-s-first-in-class-egfr-degrader-in-500m-deal 2026-04-30T05:04:19+00:00 hourly 0.9 https://trial.medpath.com/news/acrobiosystems-and-seromyx-systems-partner-to-advance-anti-cd20-monoclonal-antibody-research-through-comprehensive-functional-profiling 2026-04-30T05:04:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acrobiosystems-and-seromyx-systems-partner-to-advance-anti-cd20-monoclonal-antibody-research-through-comprehensive-functional-profiling 2026-04-30T05:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/vivacta-bio-secures-over-50-million-in-series-a-funding-to-advance-in-vivo-car-t-therapy-gt801 2026-04-30T05:04:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivacta-bio-secures-over-50-million-in-series-a-funding-to-advance-in-vivo-car-t-therapy-gt801 2026-04-30T05:04:08+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-denecimig-achieves-99-reduction-in-bleeding-episodes-for-hemophilia-a-patients-in-phase-3-trial 2026-04-30T01:04:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-s-denecimig-achieves-99-reduction-in-bleeding-episodes-for-hemophilia-a-patients-in-phase-3-trial 2026-04-30T01:04:18+00:00 hourly 0.9 https://trial.medpath.com/news/acrux-advances-female-testosterone-therapy-to-phase-iii-for-hsdd-treatment 2026-04-30T01:04:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acrux-advances-female-testosterone-therapy-to-phase-iii-for-hsdd-treatment 2026-04-30T01:04:17+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-s-mosaic-neo-mitral-valve-receives-fda-approval-launches-with-rapid-clinical-adoption 2026-04-30T01:04:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-s-mosaic-neo-mitral-valve-receives-fda-approval-launches-with-rapid-clinical-adoption 2026-04-30T01:04:02+00:00 hourly 0.9 https://trial.medpath.com/news/circular-genomics-and-vitazi-ai-partner-to-develop-ai-powered-multimodal-alzheimer-s-detection-platform 2026-04-29T21:07:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/circular-genomics-and-vitazi-ai-partner-to-develop-ai-powered-multimodal-alzheimer-s-detection-platform 2026-04-29T21:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/syncromune-s-sync-t-therapy-shows-87-response-rate-in-metastatic-prostate-cancer-phase-1-trial 2026-04-29T21:05:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/syncromune-s-sync-t-therapy-shows-87-response-rate-in-metastatic-prostate-cancer-phase-1-trial 2026-04-29T21:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/nivipit-trial-demonstrates-reduced-toxicity-with-intratumoral-anti-ctla4-in-metastatic-melanoma 2026-04-29T21:05:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nivipit-trial-demonstrates-reduced-toxicity-with-intratumoral-anti-ctla4-in-metastatic-melanoma 2026-04-29T21:05:08+00:00 hourly 0.9 https://trial.medpath.com/news/ema-launches-pilot-programme-for-breakthrough-medical-devices-and-ivds-in-q2-2026 2026-04-29T21:04:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-launches-pilot-programme-for-breakthrough-medical-devices-and-ivds-in-q2-2026 2026-04-29T21:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/lts-lohmann-expands-cdmo-services-into-ophthalmic-drug-delivery-at-new-jersey-facility 2026-04-29T17:07:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lts-lohmann-expands-cdmo-services-into-ophthalmic-drug-delivery-at-new-jersey-facility 2026-04-29T17:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/xtl-biopharmaceuticals-acquires-psyga-bio-to-create-leading-psychedelic-therapeutics-platform-following-trump-executive-order 2026-04-29T17:07:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xtl-biopharmaceuticals-acquires-psyga-bio-to-create-leading-psychedelic-therapeutics-platform-following-trump-executive-order 2026-04-29T17:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/strand-therapeutics-names-kunal-bhatia-as-cfo-to-scale-programmable-mrna-platform 2026-04-29T17:06:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/strand-therapeutics-names-kunal-bhatia-as-cfo-to-scale-programmable-mrna-platform 2026-04-29T17:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/expression-therapeutics-receives-fda-fast-track-and-rare-pediatric-disease-designations-for-hemophilia-a-stem-cell-therapy 2026-04-29T17:06:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/expression-therapeutics-receives-fda-fast-track-and-rare-pediatric-disease-designations-for-hemophilia-a-stem-cell-therapy 2026-04-29T17:06:06+00:00 hourly 0.9 https://trial.medpath.com/news/hypervision-surgical-secures-ps17m-series-a-to-advance-ai-powered-hyperspectral-imaging-technology-for-surgery 2026-04-29T17:05:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hypervision-surgical-secures-ps17m-series-a-to-advance-ai-powered-hyperspectral-imaging-technology-for-surgery 2026-04-29T17:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/bd-launches-first-all-in-one-central-line-insertion-system-to-enhance-patient-safety 2026-04-29T17:04:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bd-launches-first-all-in-one-central-line-insertion-system-to-enhance-patient-safety 2026-04-29T17:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-data-systems-innovation-accelerates-cancer-drug-approvals-reducing-patient-wait-times 2026-04-29T14:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-data-systems-innovation-accelerates-cancer-drug-approvals-reducing-patient-wait-times 2026-04-29T14:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/zumutor-biologics-secures-7-3m-series-b-to-advance-first-in-class-nk-cell-checkpoint-therapy-zm008-into-phase-2 2026-04-29T13:04:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zumutor-biologics-secures-7-3m-series-b-to-advance-first-in-class-nk-cell-checkpoint-therapy-zm008-into-phase-2 2026-04-29T13:04:55+00:00 hourly 0.9 https://trial.medpath.com/news/ptc-therapeutics-reports-positive-24-month-data-for-votoplam-in-huntington-s-disease-extension-study 2026-04-29T13:04:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ptc-therapeutics-reports-positive-24-month-data-for-votoplam-in-huntington-s-disease-extension-study 2026-04-29T13:04:14+00:00 hourly 0.9 https://trial.medpath.com/news/hutchmed-s-sovleplenib-receives-priority-review-and-breakthrough-designation-in-china-for-rare-blood-disorder 2026-04-29T13:04:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hutchmed-s-sovleplenib-receives-priority-review-and-breakthrough-designation-in-china-for-rare-blood-disorder 2026-04-29T13:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/infinite-epigenetics-acquires-tally-health-in-largest-epigenetic-age-testing-deal 2026-04-29T13:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/infinite-epigenetics-acquires-tally-health-in-largest-epigenetic-age-testing-deal 2026-04-29T13:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/mbiomics-completes-eur30m-series-a-to-advance-microbiome-cancer-co-therapy-toward-clinical-trials 2026-04-29T11:38:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mbiomics-completes-eur30m-series-a-to-advance-microbiome-cancer-co-therapy-toward-clinical-trials 2026-04-29T11:38:00+00:00 hourly 0.9